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noncompetitive antagonist interactions of the dextrorotatory opioids 3-hydroxy-N-
methylmorphinan (dextrorphan) and 3-methoxy-N-methylmorphinan (dextromethorphan)
with the N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor. Dextrorphan and
dextromethorphan potently suppressed convulsions induced by focal injection of (-)-
bicuculline methiodide into the rat prepiriform cortex with complete efficacy. The
anticonvulsant potency of an array of noncompetitive NMDA receptor antagonists was
highly correlated with their respective affinities for [3H]dextrorphan-labelled NMDA
receptors in rat forebrain membranes. These results suggest that noncompetitive
antagonism of NMDA receptors underlies the anticonvulsant action of these compounds.
In addition, 1,3-di(2-tolyl)guanidine (DTG) was found to be a potent anticonvulsant in
vivo. This novel anticonvulsant action of DTG appears not to involve either sigma binding
sites or the ion channel binding domain of the NMDA receptor.
Dextrorphan and dextromethorphan elicit stereotyped behaviour in rats that is
indistinguishable from that produced by phencyclidine. Characterization of the behavioural
potencies of several noncompetitive NMDA antagonists revealed a significant correlation
with their respective affinities for the high affinity [3H]dextrorphan binding site in rat
forebrain membranes. Furthermore, the affinity of dextromethorphan for NMDA receptors
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Chapter 1 
Introduction 
Dextrorotatory enantiomers of the morphinan series include 3-hydroxy-N­
methylmorphinan (dextrorphan) and 3-methoxy-N-methylmorphinan (dextromethorphan). 
Opioid receptors are highly stereoselective and unlike their levorotatory optical isomers, 
levorphanol and levomethorphan, the dextrorotatory opioids have virtually no affinity for 
opioid receptors. Despite their low affinity the dextrorotatory morphinans are considered 
opioid ligands; dextrorphan binds to opioid receptors with affinities approximately three 
orders of magnitude lower than levorphanol (Goldstein and Naidu, 1990). 
A number of naturally occurring and synthetic opioids possess antitussive efficacy, 
and it is this property that is responsible for the widespread use of dextromethorphan as a 
non-prescription cough suppressant since the 1950s (Bern and Peck, 1992). Dextrorphan 
also possesses considerable antitussive efficacy and is thought to contribute significantly to 
the cough suppressant effects of dextromethorphan which is rapidly and extensively 0­
demethylated to dextrorphan in vivo (Kamm et al., 1967; Ramachander et al., 1977; 
Barnhart, 1980). More recently, however, the dextrorotatory opioids have been shown to 
have anticonvulsant and neuroprotective properties by virtue of their activity as 
noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) subfamily of ionotropic 
glutamate receptors (Goldberg et al., 1987; Steinberg et al., 1988; Torte lla et al., 1988; 
Wong et al., 1988). 2 
Glutamate Receptors 
Most synapses in the central nervous system are excitatory and are believed to use 
L-glutamate as their neurotransmitter. Glutamate neurotransmission at these excitatory 
synapses is mediated via distinct receptors. Glutamate receptors not only mediate normal 
synaptic transmission via excitatory pathways, but also appear to play a key role in various 
forms of neuronal plasticity that are thought to underlie development, learning and 
memory. However, excessive glutamate release and subsequent activation of glutamate 
receptors contributes to pathologic processes such as epilepsy and neuronal degeneration 
associated with stroke, head trauma, sustained convulsions and hypoglycaemia. 
The glutamate receptors can be divided into two major groups on the basis of their 
signal transduction mechanisms; the ionotropic receptors possess integral cation-specific 
ion channels, whereas the metabotropic receptors are coupled to G-protein transduction 
elements. Ionotropic glutamate receptors have traditionally been subclassified according to 
pharmacologic criteria: the N-methyl-D-aspartate (NMDA) receptors, which are activated by 
the agonist NMDA, and the non-NMDA receptors, which include those receptors sensitive 
to the agonists a- amino -3- hydroxy -5- methyl -4- isoxazolepropionic acid (AMPA) and 
kainate (Monaghan et al., 1989; Watkins et al., 1990) (Figure 1.1). The recent molecular 
cloning of glutamate receptor subtypes has greatly extended our understanding of the 
expression, structure and properties of glutamate receptors. To date, sixteen different 
subunits have been identified for the three glutamate-gated ion channels in rodent brain 
(NMDA, AMPA and high-affinity kainate receptors); Figure 1.1 depicts a classification 
scheme based on amino acid sequence comparison and functional properties of the 
ionotropic glutamate receptor subtypes (Sprengel and Seeburg, 1995). With respect to its 
pharmacology and physiology, the NMDA receptor-channel complex is the most 
thoroughly characterized of the glutamate receptors. 3 
FIGURE 1.1. 
Ionotropic glutamate receptor subtypes and chemical structures of 
endogenous and exogenous agonists 
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The N-Methyl-D-Aspartate Receptor 
General Pharmacology. 
The NMDA receptor contains an integral channel that is highly permeable to Ca2+ 
and also permeable to Na+ and K. Increases in intracellular Ca2+ are thought to be 
responsible for both NMDA-receptor induced synaptic plasticity as well as NMDA-receptor 
mediated neuronal cell death (Monaghan et al., 1989). The NMDA receptor-channel 
complex appears to have several pharmacologically distinct modulatory domains: 
(1) a glutamate recognition site, at which NMDA is an agonist 
(2) a strychnine-insensitive glycine co-agonist site 
(3) a voltage-dependent Mg2+ site 
(4) a second divalent cation binding site defined by Zn2+ 
(5) a polyamine site and 
(6) a recognition site within the ion channel that has historically been referred to as the 
phencyclidine (PCP) receptor. 
The recognition site within the ion channel of the NMDA-receptor complex is the 
modulatory domain most relevant to the pharmacology of dextrorphan. 
A structurally diverse group of compounds appear to bind within the integral cation-
specific ion channel and exert a noncompetitive antagonism of the NMDA receptor. These 
compounds include (+)-5-methy1-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine 
(MK-801), dissociative anaesthetics (PCP and ketamine) and dextrorotatory opioids from 
the morphinan (dextrorphan and dextromethorphan) and benzomorphan (cyclazocine and 
N-allylnormetazocine (SKF 10,047)) series. The structures of noncompetitive NMDA 
antagonists most germane to this research project are given in figure 1.2. The discovery by 
Lodge and coworkers in 1982 that PCP and ketamine acted as selective noncompetitive 
antagonists of the NMDA receptor led to a series of studies which established that the PCP 
receptor and the NMDA receptor coexist as a receptor/ionophore complex (Lodge and Anis, 
1982). 5 
FIGURE 1.2.
 
Chemical structures of noncompetitive NMDA antagonists
 
dextrorphan  dextromethorphan 
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The numerous reports of recreational dextromethorphan abuse (Degkwitz, 1964; 
McCarthy, 1971) also provide an early indication of a common pharmacologic basis for the 
effects of the dextrorotatory morphinans and PCP-like drugs.  Furthermore, drug 
discrimination studies in a variety of species have suggested a common basis for the effects 
of dextrorotatory opioids and PCP-like compounds (Holtzman, 1980, 1994; Her ling et al., 
1981, 1983). This relationship was established electrophysiologically when dextrorphan, 
like PCP and ketamine (Anis et al., 1983), was reported to be a selective and potent 
antagonist of N-methylaspartate-induced excitation of spinal neurones (Church et a., 
1985).  Dextromethorphan also selectively antagonized N-methylaspartate-induced 
excitation but was 5-fold less potent than dextrorphan (Church et al., 1985). Many 
subsequent studies have indicated that although dextromethorphan is undoubtedly an 
effective noncompetitive antagonist of the NMDA receptor, it is consistently less potent 
than dextrorphan in many experimental models of NMDA receptor antagonism. Such 
reports include the ability of the dextrorotatory morphinans to attenuate hypoxic injury in 
neuronal cultures (Goldberg et al., 1987), antagonize epileptiform activity (Wong et a., 
1988; Aram et a., 1989) and protect against seizures in vivo (Leander et al., 1988; 
Chapman and Meldrum, 1989). These fmdings are supported by radioligand binding data 
in that dextrorphan is 4-fold more potent than dextromethorphan as an inhibitor of 
[3H]PCP binding (Murray and Leid, 1984) and 8-fold more potent than dextromethorphan 
as an inhibitor of [3H]dextrorphan binding (Franklin and Murray, 1992) to rat brain 
membranes. Dextromethorphan, in addition, is thought to be prototypical of a unique class 
of anticonvulsants acting through a site labelled by [3H]dextromethorphan (Torte lla et al., 
1988; 1994). The high affinity of dextromethorphan for both [3H]dextromethorphan 
binding sites (Craviso and Musacchio, 1983b) and at sigma recognition sites (Walker et a., 
1990) represent features that are unique to dextromethorphan, these pharmacologic 
characteristics are not shared by dextrorphan and are thought to be unrelated to the activity 
of dextromethorphan as an NMDA receptor antagonist. 7 
MK-801 has been used as a prototypical ligand to study noncompetitive antagonist 
interactions with the channel binding domain of NMDA receptors (Wong et al., 1986). 
However, the results of both radioligand binding studies (Franklin and Murray, 1990; 
1992) and electrophysiologic experiments (Cole et al., 1989) suggest that the mechanism of 
dextrorphan interaction with the NMDA receptor is distinctive and unlike that of MK-801. 
It is conceivable, therefore, that differences in noncompetitive NMDA antagonism may 
depend on both the mechanism of the interaction, and the specific domain of the NMDA 
receptor-channel complex with which a channel blocker interacts. The concept of multiple 
noncompetitive NMDA antagonist sites with affinity for this general class of drug, rather 
than the existence of a single binding site for all members of this drug class, has been 
suggested previously to explain the interaction of MK-801 and the noncompetitive NMDA 
antagonist desipramine on NMDA receptors (Serganor et aL, 1989). 
Molecular Biology 
The NMDA receptor-channel complex appears to exist as a hetero-oligomeric 
complex of subunits which co-assemble to form a functional channel. Two families of 
NMDA receptor subunits have recently been cloned and termed NMDAR1 (NR1) and 
NMDAR2 (NR2) in rat brain (Moriyoshi et al., 1991; Monyer et al., 1992; Ishii et al., 
1993) (Figure 1.2), and designated C and c in mouse brain (Yamazaki et al., 1992; Ikeda et 
al., 1992; Meguro et aL, 1992; Kutsuwada et al., 1992). To date, eight different isoforms 
generated by alternative splicing of mRNA have been identified for the NR1 subunit 
(Sugihara et al., 1992; Nakanishi et al., 1992; Hollman et al., 1993), whereas the NR2 
family currently consists of four closely related subunits termed NR2A-NR2D (Monyer et 
al., 1992; Ishii et al., 1993). Homomeric expression of the NR1 subunit results in a 
functional receptor that exhibits the known characteristics of the native NMDA receptor-
channel complex (Moriyoshi et al., 1991). This is in contrast to the NR2 subunits which 
show no conductance properties in response to glutamate and are thought not to form 8 
functional channels in the homomeric state. Co-expression of NR1 with an NR2 subunit, 
however, greatly potentiates responses to glutamate or NMDA and produces functional 
variability depending on the subunit combination (Meguro et al., 1992; Kutsuwada et al., 
1992; Monyer et al, 1992; Ishii et al., 1993). 
Localization of mRNA for NR1 by in situ hybridization techniques reveals an 
abundant and ubiquitous expression throughout the rat brain (Moriyoshi et al., 1991.), that 
is in marked contrast to the distinctive and restricted distribution of mRNA for NR2 
subunits (reviewed by Nakanishi 1992). The potential for regional and functional NMDA 
receptor heterogeneity has now been further extended by the recent fmdings of Laurie and 
Seeburg (1994a). Using in situ hybridization techniques to detect the location of mRNA 
for the eight possible forms of the NR1 subunit these authors reported that although some 
splice forms occur extensively and homogeneously in the adult rat brain, the occurrence of 
other splice forms is restricted to specific brain regions. Furthermore, splice variants of the 
NR1 subunit have also been shown to generate functionally distinct NMDA receptors. 
NR1 homomeric NMDA receptor channels expressed in Xenopus oocytes display 
differential sensitivity to glutamate. This differential sensitivity is dependent on the 
presence or absence of a 63 nucleotide insertion in the DNA sequence that encodes an 
additional 21 amino acid residue in the proposed extracellular amino terminal region of the 
NR1 subunit (Nakanishi et al., 1992; Sugihara et al., 1992; Hollmann et al., 1993). 
Although the subunit composition of native NMDA receptors is currently unknown, 
different NR1 splice variant and NR2 subunit combinations could theoretically produce a 
large array of pharmacologically distinct receptor subtypes. 
Although there is uncertainty with regard to the exact topology of NMDA receptor 
subunits, the following model (Figure 1.3) has been proposed based on the study of non-
NMDA receptor subunits (Holtman et al., 1994; Bennet and Dingledine, 1995). All known 
glutamate receptor subunits are thought to contain four hydrophobic domains (TMI to 
TMIV) in their structure.  Three of these domains (I, II and IV) appear to be true 9 
transmembrane spanning domains, whilst the second (II) forms a reentrant loop with both 
ends facing the intracellular side of the membrane (Bennet and Dingledine, 1995). Based 
on models for other ligand-gated ion channels, several NMDA receptor subunits are 
thought to co-assemble to form a functional cation channel. The second membrane-
dwelling domain (TMII) of each subunit is thought to be oriented in such a way that 
collectively the TMII regions of the subunits form the inside of the channel pore. 
Consequently, the second membrane-dwelling domain is thought to be important for the 
binding of noncompetitve antagonists to sites within the NMDA receptor channel. 
FIGURE 1.3.
 
Predicted structure of an NMDA receptor subunit
 10 
Recent attempts to identify the location of a noncompetitive antagonist binding 
domain within the NMDA receptor channel have utilised recombinant DNA techniques with 
a particular emphasis on the second hydrophobic domain. All known NMDA receptor 
subunits have an asparagine residue in their putative channel-forming second membrane-
dwelling segment, at a site that is homologous to the glutamine-arginine editing position 
(Q/R site) of the AMPA-kainate receptors (Nakanishi, 1992). Certain non-NMDA subunits 
possess a glutamine at the Q/R site, whilst others carry an arginine residue that appears to 
be a critical determinant of Ca2+ permeability. This arginine residue is not encoded in the 
subunit gene but is generated by an RNA editing process. Site-directed mutagenesis has 
revealed that substitution of this conserved asparagine residue in an NMDA receptor 
subunit, to glutamine or arginine, reduces the sensitivity of NMDA receptor channels to 
blockade by MK-801 (Mori et al., 1992; Sakurada et al., 1993). In a study by Kawajiri 
and Dingledine (1993), mutation of the same asparagine of NMDAR1 to an arginine 
residue resulted in a 200-fold reduction in the potency of TCP to block heteromeric NMDA 
receptors and abolished the use-dependent nature of the blockade. Furthermore, in support 
of the idea that noncompetitive antagonists may have more than one site of action on the 
NMDA receptor channel, these authors also reported a lower affmity, non use-dependent 
component of the blockade by TCP that was retained in the mutant receptor. 
Although the conserved asparagine residue in the second membrane-dwelling 
region of NMDA receptor subunits appears to influence calcium permeability and Mg2+ 
blockade of the channel (Mori et al., 1992; Burashev et al., 1992) as well as 
noncompetitive antagonist binding, it has recently been proposed that the contribution of 
this residue may differ for various noncompetitive antagonists (Yamakura et al., 1993). In 
a comparison of four heteromeric murine NMDA receptors, wild-type channels differed in 
their sensitivity to blockade by MK-801. In the same study, mutation of the asparagine 
residue reduced the sensitivity of NMDA receptor channels to blockade by PCP, ketamine 
and SKF-10,047 to different extents. These fmdings are not incongruous with the 11 
possibility of nonidentical binding sites with respect to the interaction of noncompetitive 
NMDA antagonists with the ion channel domain of the NMDA receptor . 
Noncompetitive NMDA Receptor Antagonism 
Consonant with an interaction with a site within the ion channel domain of the 
NMDA receptor, the antagonim of NMDA-evoked currents by dissociative anaesthetics 
(PCP and ketamine) has been found to be highly voltage dependent (Honey et al., 1985). 
One explanation for the voltage-dependence of NMDA receptor blockade is that the binding 
site is within the ion channel; the channel blocker must therefore move through the 
membrane electric field to reach its site. Consequently, the association rate for binding of a 
blocker to a site within the channel would be voltage dependent. This mechanism was 
originally described by Woodhull et al. (1977) to explain the voltage dependence of the 
blockade of sodium channels by protons. More recently, however, the validity of this 
model to explain dissociative anaesthetic blockade of the NMDA receptor has been 
questioned, and a guarded receptor model has been proposed that takes into account the use 
dependent nature of dissociative anaesthetic blockade (MacDonald et al., 1987; 1991). Use 
dependence of channel blockade results in a requirement for agonist activation of the 
NMDA receptor-channel complex for antagonism to occur. 
It is now generally accepted that noncompetitive antagonists attenuate NMDA 
receptor function by binding to a domain within the ion channel and that blockade can only 
occur, therefore, if the receptor is in the activated or open channel state as depicted in figure 
1.4. The primary mediators of this activation are glutamate and glycine, endogenous 
agonists at the NMDA and strychnine-insensitive glycine co-agonist sites respectively. 
The mechanisms underlying regulation of noncompetitive antagonist binding by these 
agonists have not, however, been completely elucidated. It is possible that glycine and 
glutamate increase the rate of association and dissociation of noncompetitive antagonist 12 
FIGURE 1.4.
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binding to an equal extent and thus have no net effect on equilibrium binding (Kloog et al., 
1988a; 1988b; Bonhaus and McNamara, 1988). This model implies that access to a 
channel binding site, which may be unavailable under closed channel conditions, is the 
primary determinant of noncompetitive antagonist binding. A second possibility is that 
channel opening may be coupled to an increase in the affinity of a noncompetitive 
antagonist for its binding site. A combination of the above is also conceivable whereby a 13 
noncompetitive antagonist has higher affinity for the open channel state of the NMDA 
receptor-channel complex at a site that is more accessible in the presence of glycine and 
glutamate (Foster and Wong, 1987; Reynolds et al., 1987; Johnson et al., 1988). 
Previous studies indicate that [3H]dextrorphan labels a high affinity site in rat brain 
membranes corresponding to the noncompetitive antagonist binding domain ofthe activated 
state of the NMDA receptor-channel complex (Franklin and Murray, 1990; 1992). 
Although [3H]dextrorphan appears to recognize an "open channel" binding domain 
approximating the site or sites of other specific noncompetitive NMDA antagonists, the 
binding domain of [3H]dextrorphan may not be identical to the channel binding sites of 
either [31-INK-801 or [3H] 1-[ 1- (2- thienyl)cyclohexyl]piperidine ([3H]TCP). Aspects of 
the regulation of [3H]dextrorphan binding by modulators of the NMDA receptor-channel 
complex distinguish it from  [3H]MK -801 and [3H]TCP and may be indicative  of 
underlying differences in the mechanisms of noncompetitive antagonism among these 
compounds. Specifically, the regulation of [3H]dextrorphan binding by Mg2+ and the 
polyamine agonist spermidine is insensitive to the presence of glycine and glutamate. 
Whereas the potencies ofMg2+ and spermidine as modulators of [3H]TCP and [3H]MK­
801 binding are significantly increased by the presence of exogenous glycine and glutamate 
in well washed membranes, their marked potencies as regulators of [3H]dextrorphan 
binding are unaffected by the presence or absence of these substances (Franklin and 
Murray, 1992). 
It has recently been proposed that the dissociative anaesthetic binding site may be 
located in the vestibule of the NMDA channel pore and that the NMDA channel must be 
gated open before this binding site is exposed (MacDonald et al., 1991). Channel closure 
subsequent to the binding of a dissociative anaesthetic molecule, such as ketamine or PCP, 
results in the trapping of the blocker within the closed channel (MacDonald et al., 1991). It 
is therefore possible that the apparent indifference of [3H]dextrorphan binding, to the 
presence of glycine and glutamate, is a consequence of its occupation of a more 14 
superficially located binding site, perhaps in the vestibule of the NMDA receptor ion 
channel, that is less sensitive to channel opening and closing.  As a consequence 
[3H]dextrorphan binding may be less dependent on agonist activation of the receptor. 
Further evidence for a difference in the nature of noncompetitive antagonism of 
NMDA-mediated responses by dextrorphan and MK-801 has been provided by 
electrophysiologic data (Cole et al., 1989). Unlike MK-801, which was found to act in 
clearly use-dependent manner, dextrorphan showed no evidence of use-dependency in 
producing a potent, dose-dependent and selective noncompetitive inhibition of NMDA-
mediated depolarizations in the rat hippocampal slice (Cole et al., 1989). These findings 
are not inconsistent with the possibility of dextrorphan gaining access to a site within the 
ion channel domain that is relatively exterior to that of MK-801 and which may therefore be 
less influenced by the state of the channel. Consistent with this possibility, the onset of 
dextrorphan blockade has been shown to progress slowly but completely in the 
hippocampal slice in the absence of exogenous agonist or evoked excitation; in contrast, 
onset of MK-801 blockade fails to progress under these closed channel conditions 
indicating a high degree of use-dependence (Cole et al., 1989).  In addition to the 
differential sensitivity of dextrorphan and MK-801 to glycine and glutamate, the more rapid 
kinetics of channel blockade by dextrorphan may also contribute to its lack of use-
dependency. The particularly slow time course and long duration of blockade of the 
NMDA receptor channel by MK-801 is thought to be related to its high degree of use-
dependency (Wong et al., 1986). 
Pharmacologic Consequences of NMDA Receptor Antagonism 
Anticonvulsant Effects 
Noncompetitive antagonists of the NMDA receptor possess anticonvulsant 
properties in a wide range of experimental seizure models (Aram et al., 1989; Chapman and 
Meldrum, 1989). Dextrorphan and dextromethorphan also possess significant antiepileptic 15 
activity in vitro (Wong et al., 1988; Cole et al., 1989; Aram et al., 1989) and 
anticonvulsant efficacy in vivo (Ferkany et al., 1988; Leander et al., 1988; Torte lla et al., 
1988; Chapman and Meldrum, 1989). The observation by Torte lla et al. (1988) is of 
particular interest, as dextrorphan was 2.5 times more potent than the prototypical 
anticonvulsant compound phenytoin, in suppressing maximal electroshock-induced 
convulsions in rats. Similarly, dextrorphan and other noncompetitive antagonists protect 
against sound-induced seizures in DBA/2 mice (Chapman and Meldrum, 1989). 
Moreover, for MK-801, PCP, dextrorphan, SKF 10,047 and ketamine an excellent 
correlation exists between their relative anticonvulsant potencies and their respective 
affinities as inhibitors of [3H]MK -801 binding to brain membranes (Chapman and 
Meldrum, 1989). 
Neuroprotective Effects 
The neurotoxic properties of glutamate have been proposed to contribute to the 
pathogenesis of human neuronal cell loss associated with several neurologic disease states 
(Rothman and Olney, 1987; Choi et al., 1988). The high calcium permeability of the 
NMDA subtype of glutamate receptors provides support for the hypothesis that glutamate 
neurotoxicity is largely mediated by an influx of calcium into the cell (Choi et al., 1988). It 
is not surprising, therefore, that selective NMDA receptor antagonists have been shown to 
have neuroprotective effects in both neuronal culture and animal models (Choi et al., 1988; 
Goldberg et al., 1988).  Presumably by virtue of their NMDA antagonist activity, 
dextrorphan and dextromethorphan are also effective neuroprotectant agents and reduce the 
magnitude and extent of neuronal damage following ischaemic or traumatic brain insult in 
vivo (Steinberg et al., 1988, 1989; Faden et al., 1989), or that resulting from hypoxic, 
glutamate or hypoglycaemic challenge in vitro (Goldberg et al., 1987; Choi et al., 1987; 
Monyer and Choi, 1988). 16 
Given the established safety record in humans of dextromethorphan at antitussive 
doses, the dextrorotatory opioids are considered attractive candidates for clinical 
investigation.  It has been proposed that dextrorphan may of particular benefit for the 
treatment of patients with an acute stroke, a major neurological deficit, or those undergoing 
surgery carrying high risks of cerebral ischaemia (Steinberg et al., 1991). 
Psychoactive Effects 
The dextrorotatory morphinans have virtually no affmity for opioid receptors and 
thus lack the potent analgesic properties, respiratory depressant effects and morphine-like 
addictive potential associated with related levorotatory opioid isomers (Isbell and Fraser, 
1953). Although devoid of morphine-like effects and consequently considered non­
addictive (Isbell and Fraser, 1953) the dextrorotatory morphinans, at levels exceeding the 
recommended antitussive dose, can induce a PCP-like syndrome presumably by virtue of 
their activity as noncompetitive antagonists of the NMDA (N-methyl-D-aspartate) subfamily 
of ionotropic glutamate receptors. 
PCP is an intravenous anaesthetic agent that exhibits marked psychotomimetic 
activity in humans when administered at subanaesthetic doses (Luby et al., 1959). In 
1957, PCP was introduced for clinical trials as a general intravenous anaesthetic 
(Greifenstein et al., 1958). Although PCP was found to be generally effective as an 
anaesthetic, its use was associated with a high incidence of postoperative emergence 
reactions. These emergence reactions included marked agitation, excitement, disorientation 
and hallucinations (Lear et al., 1959). The incidence of these reactions was considered 
clinically unacceptable and the subsequent search for a PCP analogue with a reduced 
propensity to produce emergence phenomena led to the development of ketamine. 
Numerous reports of recreational dextromethorphan abuse (Degkwitz, 1964; 
McCarthy, 1971) provide an early indication of a common pharmacologic basis for the 
effects of the dextrorotatory morphinans and PCP-like drugs. In 1964 Degkwitz reported 17 
sedative-hypnotic effects, slurred speech, pupillary dilation, sensory distortion, 
drunkenness and euphoria in patients that had ingested 300 mg (approximately 10 times the 
antitussive dose) of dextromethorphan. In a later study of the effects of dextromethorphan 
in humans, Jasinski et al. (1971) confirmed the presence of sedative-hypnotic and 
psychotomimetic effects following consumption of doses approximately 8 times higher 
than the recommended antitussive dose, and also noted that the subjective response to 
dextromethorphan was clearly different to that of morphine. Furthermore, the results of 
many drug discrimination studies have suggested a common mode of action for the effects 
of dextrorotatory opioids and PCP-like compounds Holtzman, 1980, 1994; Her ling et al., 
1981, 1983). 
Objectives 
The intent of these studies was to increase our understanding of the interaction of 
dextrorotatory opioids with the NMDA receptor. Whole animal studies and quantitative 
receptor autoradiography were utilised in this research project, the specific aims of which 
are detailed below. 
Chapter 2 describes studies to investigate the ability of dextrorphan and 
dextromethorphan to suppress convulsions induced by focal injection of a 
chemoconvulsant into the rat prepiriform cortex.  Intracerebral injection of 
chemoconvulsants into the prepiriform area initiates generalized motor seizures in the rat, 
thus providing a useful animal model with which to evaluate the protective effects of 
noncompetitive NMDA antagonists. In addition, the anticonvulsant effects of PCP, MK­
801 and the sigma (a) ligand (+)-pentazocine were also studied as reference compounds in 
this model to allow comparison of the rank order of potency of these compounds with their 
respective affinities for the [3Ifidextrorphan binding site in vitro. 
Chapter 3 documents a novel anticonvulsant action of the a ligand 1,3-di(2­
toly)guanidine (DTG). Sigma receptors were originally thought to be a type of opiate 18 
receptor, however, two subsequent findings revealed that they are not: (1) naloxone is an 
ineffective antagonist of the effects of sigma ligands in vivo and in vitro and (2) whereas 
opiate receptors are selective for the levorotatory enantiomers of opium-derived 
compounds, sigma receptors are selective for dextrorotatory enantiomers. Initial studies 
suggested that sigma receptors were PCP receptors, however, the pharmacologic profile 
and anatomical distribution of sigma and PCP binding sites clearly demonstrates that they 
are not the same.  Pharmacologic characterization of sigma binding sites remains 
ambiguous and their physiological relevance has yet to be established. DTG, however, 
displays a potent and efficacious anticonvulsant effect in the rat prepiriform cortex by a 
mechanism that does not involve a receptors. Noncompetitive antagonism of NMDA 
receptor-mediated excitation at the MK-801 / PCP binding site is also unlikely to account 
for the protective effects of DTG reported in this chapter. (The site of injection in the 
prepiriform cortex for the compounds described in chapters 2 and 3 was sampled and 
examined histologically (Figure 1.5.)). 
Chapter 4 describes studies in which the ability of dextrorphan and 
dextromethorphan to induce stereotyped behaviour in the rat were investigated. A possible 
correlation of the rank order of potencies of an array of noncompetitive NMDA antagonists 
to induce stereotyped behaviour in male Sprague-Dawley rats and their respective affinities 
for the high- affinity [3H]dextrorphan binding site in rat forebrain membranes was also 
assessed. To further investigate dextrorotatory opioid-induced stereotypies and to 
specifically address the propensity of dextromethorphan to induce this behaviour, studies 
were done using female Sprague-Dawley and female Dark Agouti rats. The female Dark 
Agouti rat is deficient in the cytochrome P450 enzyme 2D1 which catalyses the 0­
demethylation of dextromethorphan to dextrorphan in the Sprague-Dawley rat strain. 
Chapter 5 describes studies that were undertaken to investigate the anatomical 
distribution of [3H]dextrorphan binding sites in rat brain using quantitative receptor 
autoradiography. A procedure for quantitative autoradiographic visualization of 19 
[3H]dextrorphan binding sites in slide-mounted sections was defined and the specificity of 
the autoradiographic assay for the labelling of a site within the ion channel domain of the 
NMDA receptor confirmed. To gain further insight into the mechanism by which 
[3H]dextrorphan interacts with the NMDA receptor-operated cation channel, the regulation 
of [3H]dextrorphan binding by glycine and glutamate was assessed in several brain areas. 
In addition, the regional distribution of [3H]dextrorphan binding sites in the rat brain was 
compared to previously reported distributions of NMDA receptors determined by receptor 
autoradiography 20 
FIGURE 1.5.
 
Schematic drawings of coronal rat brain sections showing the location of
 
microinjection sites in the prepiriform cortex.
 
The location of the cannula tip was determined histologically in a series of 16-gm coronal 
sections stained with cresyl violet. Drawings are in accordance with the stereotaxic rat 
brain atlas of Paxinos and Watson (1986). Filled circles indicate sites most sensitive for 
evoking seizures (score z 4) in response to unilateral focal injection of 118 pmol (-)­
bicuculline methiodide (BMI). Half filled circles indicate partial response to BMI (score 1­
3). Open circles indicate no response to BMI. The plane of the sections shown for 
histologic reference is the same as the plane of cannula penetration. Abbreviations: cc, 
corpus callosum; lot, lateral olfactory tract; PPC, prepiriform cortex. FIGURE 1.5.
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Abstract 
We have investigated the ability of an array of putative noncompetitive N-methyl-D­
aspartate (NMDA) receptor antagonists to suppress convulsions induced by a unilateral, 
focal injection of (-)-bicuculline methiodide (118 pmol) into the rat prepiriform cortex. The 
anticonvulsant potency of these compounds, (+)-5-methyl-10,11-dihydro-5H­
dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801) > dextrorphan  141­
phenylcyclohexyl)piperidine hydrochloride (PCP) > dextromethorphan > (+)-pentazocine, 
upon microinjection into the prepiriform cortex, was highly correlated (r=0.971; P < 0.01) 
with their respective affinities for the [3H]dextrorphan- labelled NMDA receptors in rat 
forebrain membranes. These results suggest that noncompetitive antagonism of NMDA 
receptors underlies the anticonvulsant action of these compounds. 24 
Introduction 
Noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) class of 
excitatory amino acid receptors, such as 1- (1- phenylcyclohexyl)piperidine hydrochloride 
(PCP) and (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen 
maleate (MK-801), are known to possess anticonvulsant properties. The dextrorotatory 
opioids, dextrorphan and its 3-methyl ether derivative dextromethorphan, also exhibit 
anticonvulsant activity in vivo in several seizure models (Ferkany et al., 1988; Leander et 
al., 1988; Tortella et al., 1988; Chapman and Meldrum, 1989). The observation by 
Torte lla et al. (1988) is of particular interest, as dextrorphan was 2.5 times more potent 
than the prototypical anticonvulsant compound phenytoin, in suppressing maximal 
electroshock-induced convulsions in rats. In spite of the apparent similarity of dextrorphan 
and dextromethorphan to other noncompetitive NMDA antagonists, the basis for their 
anticonvulsant effects in vivo has not been clearly established. 
We have recently described a specific binding site for [31I]dextrorphan in rat 
forebrain membrane preparations (Franklin and Murray, 1990). The pharmacological 
profile of [3H]dextrorphan binding and its regulation by modulators of NMDA receptor 
activity is consistent with the labelling of a site associated with the NMDA receptor cation 
channel complex. 
The aim of this study was to investigate the ability of dextrorphan and 
dextromethorphan to suppress convulsions induced by a focal injection of (-)-bicuculline 
methiodide (BMI) into the rat prepiriform cortex. Initially reported by Pirreda and Gale 
(1985), the prepiriform area appears to play an important role in initiation of generalized 
motor seizures in the rat. In addition, the anticonvulsant effects of PCP, MK-801 and the 
a ligand (+)-pentazocine were also studied as reference compounds in this model to allow 
comparison of the rank order of potency of these compounds with their respective affinities 
for the [311]dextrorphan binding site in vitro. 25 
Materials and Methods 
Stereotaxic surgery 
Male Sprague-Dawley rats (330-400 g; Simonsen Laboratories, Gilroy, CA) were 
maintained at 22°C on a standard 12 h light-dark schedule, with food and water available ad 
libitum. Animals, under Equithesin anesthesia (2.7 ml/kg i.p.), were placed in a Kopf 
small animal stereotaxic instrument and implanted with paired, 22 and 28 gauge guide and 
injection cannulas, respectively. With the incisor bar at -3.2 to -3.5 mm to achieve a 'flat 
brain' orientation in accordance with the stereotaxic atlas of Paxinos and Watson, the 
cannulas were aimed at a site in the anterior prepiriform cortex 2.0 mm anterior and 3 3 mm 
lateral to bregma, at a depth of 6.5 mm below dura as described in our previous studies 
(Franklin et al., 1989). Animals were housed individually and allowed at least 24 h 
recovery before experimentation. 
Microinjection protocol 
Intracerebral microinjection procedure has been described previously (Franklin et 
al., 1989). All test compounds were dissolved in deionized water with the exception of 
(+)-pentazocine (100 mM phosphoric acid, fmal pH 5.0) and injected into the prepiriform 
cortex in a volume of 1 g 1 at a rate of 4 nl/s.  Limited aqueous solubility of 
dextromethorphan and (+)-pentazocine in their injection vehicles prevented microinjection 
of doses higher than 85 and 105 nmol, respectively. All experiments were done during the 
12 h light cycle. 
Evaluation of anticonvulsant efficacy 
Cannula placement in the prepiriform cortex was verified by the behavioural 
response of each animal to a 118 pmol dose of BMI on day 1. Animals were observed 30 
min and stereotypical seizure behaviour quantified by assignment of a maximum seizure 
score ranging from 0 to 5 on a scale of increasing seizure severity. This scale is derived 26 
from that of Racine and described in detail elsewhere (Franklin et al., 1989). Only animals 
showing seizure scores of 4 or 5 on the first day, were included in the study. 
Anticonvulsant activity of test compounds was evaluated on the following day by 
microinjection 15 min prior to the chemoconvulsant. Absence or reduction of BMI-induced 
seizure behaviour after drug treatment was only confirmed as an anticonvulsant response, if 
the same dose of BMI elicited a positive response in post-test on the third day. Cannula 
placement was routinely confirmed by histological examination in this population of 
animals at the end of their participation in experiments and also in animals failing to show 
an initial sensitivity to BMI on day 1. 
Protective effects were determined as the percentage reduction in mean seizure score 
from control for groups of animals at each dose level. Dose-response curves were fit to 
data sets by means of an iterative nonlinear least-squares regression analysis to a 
rectangular hyperbola defined by the following equation: 
E=  E'
* D 
EDP + D 
where E is the % reduction in seizure severity and D represents the dose (lig). 
Results 
Unilateral focal injection of each test compound produced no change in behaviour 
during the 15 min pretreatment epoch. As shown in figure 2.1, all compounds protected 
against BMI-induced convulsions in the prepiriform cortex in a dose dependent manner. 
MK-801 was the most potent anticonvulsant tested, with an ED50 value (± S.E.) of 4.07 ± 
0.8 nmol. Dextrorphan and PCP also potently suppressed convulsions with complete 
efficacy; ED50 values were 17.08 ± 7.9 and 20.30 ± 6.9 nmol respectively. 
Dextromethorphan was approximately 4-fold less potent than dextrorphan, with an ED50 27 
FIGURE 2.1.
 
Protective effects of MK-801, dextrorphan (DX), phencyclidine (PCP),
 
dextromethorphan (DXM) and (+)-pentazocine ((+)PEN) against seizures
 
induced by (-)-bicuculline methiodide (BMI) in the rat prepiriform cortex.
 
All compounds were injected unilaterally, at the doses indicated, 15 min prior to a 
challenging dose of BMI (118 pmol). Animals were observed for 30 min and the highest 
seizure score determined for each animal. For a representative compound such as 
dextrorphan the coefficient of variation for mean seizure scores ranged from 11.8 % at a 
dose of 0.3 nmol to 0 % at the 25 nmol dose. Values represent the reduction in seizure 
score from the mean control response to BMI at each dose group (n = 3-10). 
FIGURE 2.2.
 
Correlation between the potencies of noncompetitive NMDA antagonists  as
 
anticonvulsants and their respective affinities for the [3H]dextrorphan
 
binding site in rat forebrain membranes.
 
The potencies (nmol) of MK-801, dextrorphan (DX), phencyclidine (PCP), 
dextromethorphan (DXM) and (+)-pentazocine ((+)PEN) to protect against BMI- induced 
seizures were highly correlated (r = 0.971; P < 0.01) with their respective dimities for the 
[3H]dextrorphan binding site in rat forebrain membranes. IC50 values (nM) are taken from 
Franklin and Murray (1992), except (+)PEN (unpublished observation). FIGURE 2.1.
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value of 81.57 ± 32.0 nmol. The ED50 value of (+)-pentazocine could not be determined 
due to the marginal efficacy of this compound; a dose of 105 nmol afforded only 31% of 
maximum protection. 
The correlation between the potency of compounds to protect against convulsions 
induced by BMI in the prepiriform cortex and their ability to inhibit [3H]dextrorphan 
binding in rat forebrain membranes is shown in figure 2.2. Linear regression of the log 
transformed data gave a correlation coefficient of 0.971 (P < 0.01). These data suggest 
that cortical NMDA receptors  mediate the observed anticonvulsant actions of the 
compounds tested. 
Discussion 
Although the anticonvulsant activity of dextrorphan and dextromethorphan is 
comparable to that of other noncompetitive NMDA antagonists, the underlying mechanism 
of action has remained less certain. The rapid metabolism of dextromethorphan to 
dextrorphan following peripheral administration, has been a complicating factor in the 
interpretation of some studies in vivo.  In addition, binding sites for [3H]dextromethorphan 
have been identified and  characterized in guinea pig brain, but appear  to be 
pharmacologically unrelated to the NMDA antagonist activity of dextromethorphan 
(Craviso and Musacchio, 1983b). a Ligands such as (+)-3-PPP ((+)-3-(hydroxypheny1)­
N-propylpiperidine hydrochloride),  (+)-SKF-10047 ((+)-N-allyl-N-normetazocine 
hydrochloride) and haloperidol have been shown to inhibit [3H]dextromethorphan binding; 
Although however, dextrorphan interacts at this site with a very modest affinity. 
[3H]dextromethorphan binding is positively modulated by phenytoin, and phenytoin 
appears to increase the anticonvulsant potency  of dextrorphan against maximal 31 
electroshock-induced seizures, the role of this site in the anticonvulsant actions of 
dextrorphan and dextromethorphan remains to be established. 
From our fmdings it is apparent that the anticonvulsant efficacy of dextrorphan and 
dextromethorphan, in the prepiriform cortex, is comparable to that of PCP and MK-801. 
Furthermore, the anticonvulsant potencies of the compounds tested were highly correlated 
with their respective affinities for the [3H]dextrorphan-labelled NMDA receptors in rat 
forebrain membrane preparations (Franklin and Murray, 1992). A 4-fold difference in the 
anticonvulsant potency of dextrorphan and dextromethorphan, reported herein, compares 
favourably to an 8-fold greater potency of dextrorphan over dextromethorphan to inhibit 
[3H] dextrorphan binding. This correlation is consonant with an NMDA receptor-mediated 
anticonvulsant action of these compounds. Moreover, this observation is consistent with a 
proposed NMDA receptor-modulated output pathway from the prepiriform cortex, thought 
to be essential for the generation of seizures from this brain area. 
These data are in agreement with other studies that have shown dextromethorphan 
to be less potent than dextrorphan in experimental models of NMDA antagonism in vivo. 
The anticonvulsant doses in the prepiriform cortex, reported herein, were comparable to 
i.c.v. doses required to protect against sound-induced seizures in DBA/2 mice (Chapman 
and Meldrum, 1989). Moreover, dextromethorphan was also less potent than dextrorphan 
in protecting against maximal electroshock-induced seizures in mice (Leander et al., 1988). 
The relatively weak action of (+)-pentazocine lends further support for an association 
between anticonvulsant activity and noncompetitive antagonism of NMDA receptors. 
Although reported to have weak NMDA antagonist activity, the (+) isomer of pentazocine 
has high affinity for the a receptor (Church and Lodge, 1990). 
In summary, by direct intracranial administration we have studied the ability of a 
series of putative NMDA antagonists, in the absence of dispositional influences, to 
suppress BMI-induced convulsions following focal injection into the prepiriform cortex. 
The correlation of this pharmacological profile with that defined by [3H]dextrorphan 32 
equilibrium competition binding studies suggests that interaction with the NMDA receptor 
cation channel complex mediates the anticonvulsant actions of the dextrorotatory opioids, 
PCP and MK-801 in the prepiriform cortex. Further characterization of the anticonvulsant 
effects of noncompetitive NMDA antagonists in this brain region will provide a better 
understanding of both their underlying mechanisms of action and promise as therapeutic 
agents in the treatment of epilepsy. 
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Abstract 
Unilateral focal injection of 1,3-di(2-tolyl)guanidine (DTG) caused a dose-
dependent and potent (ED50 = 5.25 nmol, 95 % confidence limits 1.1 to 25.0 nmol) 
suppression of generalind motor seizures induced by (-)-bicuculline methiodide in the rat 
prepiriform cortex. These findings indicate that DTG is equipotent to the noncompetitive 
NMDA receptor  antagonist MK-801  ((+)-5-methyl -10,  11-dihydro-5H­
dibenzo[a,d]cyclophepten-5,10-imine hydrogen maleate) as an anticonvulsant. This potent 
pharmacological effect DTG distinguishes it from two other prototypic a ligands, 
haloperidol and (+)-pentazocine, which are ineffective as anticonvulsants. Pretreatment of 
animal with haloperidol failed to block the anticonvulsant effects of DTG. These data 
therefore document a novel anticonvulsant action of DTG in vivo that does not involve a 
receptors. 35 
Introduction 
1,3-Di(2-toly)guanidine (DTG) was synthesized by Weber and coworkers (1986) 
and has been considered a prototypic ligand for a binding sites. Although regarded as 
distinct from the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA) 
receptor cation channel complex, pharmacological characterization of a binding sites 
remains ambiguous and their physiological relevance has yet to be established.  In 
particular, progress has been hindered both by the absence of a consistent agonist / 
antagonist profile and the heterogeneity of binding characteristics amongst currently 
available a ligands. 
Sigma (a) sites have recently been subclassified, largely on the basis of biochemical 
and radioligand binding data, further underscoring the importance of DTG as a 
pharmacological tool. Under the proposed classification scheme DTG and haloperidol do 
not discriminate between al and a2 subtypes and therefore, in the absence of selective 0,2 
ligands, DTG has become especially valuable in the study of the putative a2 site. 
Additionally, there have been several reports documenting effects of DTG that may 
not be attributed to its a binding properties, and have thus raised the possibility that DTG 
may have pharmacological activity independent of its action at a sites (Holtzman, 1989; 
Walker et al., 1990; Connick et al., 1992). We now report that DTG potently protects 
against convulsions induced by (-)-bicuculline methiodide in the rat prepiriform cortex in a 
manner that its neither mimicked nor blocked by haloperidol. 
Materials and Methods 
Male Sprague-Dawley rats (340-390 g; Simonsen Laboratories, Gilroy, CA) were 
anaesthetised and stereotaxically implanted with paired guide and injection cannulas, aimed 
at a site in the anterior prepiriform cortex as described previously (Roth et al., 1992). 
Cannula placement was verified 24-48 h later by the behavioural response of each animal to 36 
a single microinjection of 118 pmol of (-)-bicuculline methiodide, dissolved in normal 
saline and administered at a rate of 0.9 nl/s in a volume of 120 nl. Following injection rats 
were observed for 30 min and stereotypical seizure behaviour quantified by a seizure 
scoring system derived from that of Racine (1972). A maximum seizure score ranging 
from 0 to 5 was assigned to each animal as follows: (0) no seizure; (1) myoclonic jerks of 
the forelimb contralateral to the injection; (2) mild forelimb clonus (± mouth and facial 
movements-clonus of jaw and head nodding) lasting at least 5 s; (3) severe forelimb dorms 
lasting more than 15 s; (4) rearing concomitant to or succeeding an instance of forelimb 
clonus; (5) loss of balance or falling concomitant to or succeeding an incident of rearing. 
Only rats showing seizure scores 4 or 5 on the first (control) day were used for subsequent 
studies. 
The following day DTG was focally injected 15 min before (-)-bicuculline 
methiodide. If animals showed a reduced seizure score, an anticonvulsant response of 
DTG pretreatment was confirmed by post-test with (-)-bicuculline methiodide on the third 
day. Any animal showing a loss of sensitivity to (-)-bicuculline methiodide (seizure score 
less than 4 or 5) was excluded from the study. Protective effects were calculated as the 
percentage reduction in seizure score from the mean control response to (-)-bicuculline 
methiodide at each dose group. The ED50 value was calculated using the method of 
Litchfield and Wilcoxon (1949), a minimum of four animals was used for each dose group. 
Dose-response data were further analysed by iterative nonlinear least-squares regression 
analysis to generate a sigmoid curve defined by the logistic equation: 
E=  E. 
1+ (EA° 1 [D]) 
where E represents the % reduction in seizure severity and D is the dose (nmol). 
To investigate the effects of haloperidol on the protective action of DTG against (-)­
bicuculline methiodide-induced seizures, animals from two separate groups received a focal 
injection of haloperidol (10.6 nmol) either alone or followed 15 min later by a single dose 37 
of DTG (12.5 nmol), 30 min prior to (-)-bicuculline methiodide. In all studies DTG and 
haloperidol were dissolved in 60 mM phosphoric acid and the pH adjusted to 5.0 with 
sodium hydroxide. Both compounds were injected at a rate of 4 nl/s in a total volume of 1 
Results 
DTG protected against convulsions induced by (-)-bicuculline methiodide in the rat 
prepiriform cortex in a highly potent manner, the ED50 value, with 95% confidence limits, 
was 5.25 (1.1 to 25.0) nmol. As shown in figure 3.1, DTG afforded a dose-dependent 
reduction in seizure behaviour that reached 81% efficacy at the highest dose tested. The 
limited aqueous solubility precluded testing of higher doses of DTG. Unilateral focal 
injection of DTG into the prepiriform cortex produced no change in behaviour during the 
15 min pretreatment epoch, nor did it induce any signs of motor dysfunction during the 
course of the study. A separate group of animals pretreated with vehicle showed no 
reduction in seizure score (Table 3.1). 
In contrast to the effects of DTG, unilateral focal injection haloperidol (10.6 nmol) 
into the prepiriform cortex failed to protect against (-)-bicuculline methiodide-induced 
seizures (Table 3.1). When haloperidol was administered 15 min prior to a known 
anticonvulsant dose of DTG, the effects of DTG were not changed. As shown in table 3.1, 
12.5 nmol of DTG still afforded 79% protection against (-)-bicuculline methiodide-induced 
seizures in animals pretreated with haloperidol. Hence haloperidol neither mimics nor 
antagonizes the anticonvulsant action of DTG. 38 
FIGURE 3.1.
 
Anticonvulsant effect of DTG against seizures induced by (-)-bicuculline
 
methiodide in the rat prepiriform cortex.
 
On day 1 animals received a single microinjection of (-)-bicuculline methiodide (118 pmol) 
and were observed for 30 min.  Stereotypical seizure behaviour was quantified by 
assignment of a score ranging from 0 to 5 on a scale of increasing seizure severity; only 
rats showing scores of 4 or 5 were used for subsequent studies. The following day DTG 
was focally injected 15 min prior to (-)-bicuculline methiodide (118 pmol) and the highest 
seizure score determined for each animal during a 30 min epoch. Ordinate values represent 
the reduction in seizure score from the mean control response to (-)-bicuculline methiodide 
at each dose group (n = 4-6). The symbols describe the actual data points and the curve 
represents the dose-response relationship described by the parameter estimates obtained by 
fitting a logistic equation to the data by iterative nonlinear least-squares regression analysis. 
Inset shows the regression line of probit values versus log dose (nmol). 39 
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TABLE 3.1. 
Failure of haloperidol to protect against (-)-bicuculline 
methiodide-induced seizures or antagonize the anticonvulsant 
action of DTG in the rat prepiriform cortex 
Mean  % 
Treatment  Distribution of Seizure Scores  Seizure  Protection 
0  1  2  3  4  5 Score (n) 
Control  4  2  4.33 
Vehicle  6  5.00 (6)  0 
Control  1  3  4.75 
DTG  3  1  1.25 (4)  74 
Post-test  2  1  4.33 
Control  1  4  4.80 
Haloperidol  1  4  4.80 (5)  0 
Control  1  4  4.80 
Haloperidol + DTGa  4  1  1.00 (5)  79 
Post-test  2  2  4.50 
All compounds were microinjected unilaterally into the prepiriform cortex; a 
haloperidol (10.6 nmol) was administered 15 min prior to DTG (12.5 nmol), which 
was given 15 min before (-)-bicuculline methiodide. Animals were observed for a 
30 min epoch following (-)-bicuculline methiodide and the highest seizure score 
attained for each animal. The distribution of seizure scores, for animals within each 
treatment group of size (n), are tallied under numerical columns corresponding to 
each level of seizure severity as defined in the text.  Responsiveness to (-)­
bicuculline methiodide (118 pmol) was confirmed in all animals showing a reduced 
seizure score by post-test the following day.  Percent protection reflects the 
reduction in mean seizure score from the control response to 118 pmol (-)­
bicuculline methiodide. 41 
Discussion 
We have recently shown that antagonism of NMDA receptors underlies the ability 
of an array of dextrorotatory opioids and PCP to protect against (-)-bicuculline methiodide­
induced convulsions in the rat prepiriform cortex (Roth et al., 1992). In that study the 
selective al ligand (+)-pentazocine had limited anticonvulsant efficacy, thereby arguing 
against a role for al sites in the mediation of this response; a dose of 105 nmol (+)­
pentazocine afforded only 31% of maximal protection. In contrast, the results of the 
present study indicate that DTG is both an efficacious and potent anticonvulsant against (-)­
bicuculline methiodide-induced seizures. By comparison, DTG (ED50 = 5.25 nmol) was 
equipotent to MK-801, the prototypical noncompetitive NMDA antagonist, and greater than 
20-fold more potent than (+)-pentazocine; whereas DTG and (+)-pentazocine are essentially 
equipotent at the [3H]DTG- labelled a binding site (Weber et al., 1986). 
The clear disparity between the respective affinities of DTG and (+)-pentazocine for 
a sites in vitro and their anticonvulsant activities in vivo led us to investigate the ability of 
haloperidol to modulate (-)-bicuculline methiodide-induced seizures in the prepiriform 
cortex. Haloperidol is a reference compound with a high affinity for a sites labelled by a 
variety of ligands such as [3H]( +) -SKF 10,047 ([3H]( +)- N- allylnormetazocine), [311](+)­
pentazocine, [3H]3 -PPP ([311]3-(3-hydroxypheny1)-N-(1-propyl)piperdine) and [3H] DTG 
(Walker et al., 1990). Consequently, a high affinity for haloperidol has become one of the 
hallmarks of a site characterization. In addition, haloperidol, like DTG, is thought to act 
with high affinity at the al and a2 binding sites. The results of our present study indicate, 
however, that haloperidol does not exhibit the marked seizure suppressant effects shown 
by DTG. Focal administration of haloperidol in a dose (10.6 nmol) 2-fold greater than the 
ED50 dose of DTG, failed to produce any anticonvulsant response against (-)-bicuculline 
methiodide-induced seizures. It therefore seems unlikely that the anticonvulsant action of 
DTG is mediated by either at or a2 sites inasmuch as haloperidol has 40-fold greater 42 
affinity than DTG for the [3H]DTG labelled al binding site and is equipotent to DTG at the 
[3H]DTG labelled a2 binding site (Rothman et al., 1991). 
We also pretreated animals with haloperidol in an attempt to block the 
anticonvulsant effects of DTG, but were unable to demonstrate a antagonist properties of 
haloperidol similar to those recently described by Monnet et al. (1992). These authors 
distinguished two classes of a ligands based on their ability to modulate NMDA-evoked 
excitation of rat CA3 hippocampal neurones: a agonists produced a selective potentiation 
of the NMDA response; a antagonists, which included haloperidol, had no effect alone but 
suppressed the a agonist-induced potentiation of the NMDA response.  Although 
identification of selective agonists and antagonists will eventually be an integral part of 
determining the functional relevance of a sites, the proposed a antagonist status of 
haloperidol should be viewed with caution as the majority of reports in the a literature have 
shown haloperidol to be a a agonist. In particular, previous attempts to correlate the 
binding affinity of a ligands with activity in a functional assay, such as the ability to cause 
dystonia in the rat following injection into the red nucleus, inhibition of agonist-stimulated 
phosphoinositide turnover and inhibition of electrically or serotonin-evoked contractions of 
the guinea-pig ileum, have all shown haloperidol to be a more potent a agonist ligand than 
DTG (Walker et al., 1990). The general inability of haloperidol to modulate (-)-bicuculline 
methiodide-induced seizures further argues against an association between a activity and 
the anticonvulsant effect of DTG in the prepiriform cortex. 
Noncompetitive antagonism of NMDA receptor-mediated excitation at the MK-801 / 
PCP binding site is also unlikely to account for the protective effects of DTG reported 
herein. Radioligand binding experiments have shown DTG to have low affmity for 
[3H]MK -801 and [3H]TCP 141-( 2-thienyl)cyclo hexyl] piperidine-labelled NMDA 
receptors in rat and guinea-pig brain membranes (Keana et al., 1989). Furthermore, DTG 
was 500 times less potent than MK-801 as an antagonist of NMDA-evoked depolarizations 
in rat neocortical slices (Aram et al., 1989). It is interesting, however, to note that DTG 43 
was equipotent to MK-801 in its ability to induce PCP-like stereotyped behaviour and 
ataxia in rats following i.c.v. administration (Contreras et al., 1988).  This rather 
surprising observation could not be explained by the relative order of potency for DTG and 
MK-801 to displace [3H]TCP, [311](+)-SKF 10,047 or [3H]( +) -3 -PPP from rat whole 
brain membrane preparations. Thus the mechanism of DTG-induced stereotyped behaviour 
remains to be delineated. Consistent with our own finding in vivo, the pharmacological 
profile for DTG-ble discriminative effects was also not predicted by affinity for either PCP 
or a binding sites (Holtzman, 1989). 
Of potential relevance to the anticonvulsant response observed in our investigations, 
there are now a number of reports showing that DTG has a potent inhibitory effect on both 
spontaneous and induced neuronal firing; none of which can be definitively related to a 
direct action at the putative a receptor (Walker et al., 1990). In a recent study by Connick 
et al. (1992), DTG reversibly inhibited NMDA and quisqualate induced firing in cortical 
and hippocampal neurones in a haloperidol insensitive manner. Similarly, Fletcher et al. 
(1992) found DTG to be a potent and voltage-dependent antagonist of NMDA-evoked 
depolarization in rat hippocampal neurones. Other investigators have found that DTG 
exhibits a distinct pharmacological profile when compared to other a ligands in a variety of 
experimental paradigms. French and Ceci (1990) reported that DTG produced a 10% 
depression in the firing rate of A13 dopamine neurones which was in marked contrast to the 
stimulatory action of (+)-pentazocine. In addition, DTG has been found to have anomalous 
excitatory properties in that it was 3-fold more efficacious than other a ligands, including 
(+)-pentazocine, in potentiating NMDA-induced excitation of rat CA3 hippocampal 
neurones (Monnet et al., 1992). These latter authors also reported an inhibitory effect of 
DTG at high doses but not for other a ligands. Atypical responses to DTG have also 
occurred in peripheral tissues. Kennedy and Henderson (1989) noted that, unlike other a 
ligands, DTG failed to potentiate electrically evoked neurogenic twitch contractions of the 
mouse isolated vas deferens and in fact produced inhibition of the response at high doses. 44 
Excitatory mechanisms are thought to play an integral role in the generation of 
seizures from the prepiriform cortex. The suppression of such excitatory amino acid 
transmission by DTG, perhaps by a direct receptor level antagonism of depolarization 
mediated by activation of excitatory amino acid receptors, or indirectly through inhibition of 
excitatory neurotransmitter release, offers a possible explanation for the anticonvulsant 
response observed in vivo and is consistent with the inhibitory properties frequently 
observed with DTG. Whilst it is also interesting to note that autoradiographic studies of 
[3H}DTG binding to rat and guinea-pig brain sections revealed dense binding in the 
piriform cortex (Weber et al., 1986), it would be unwarranted, given the distinct 
pharmacological profile of DTG in this model, to attribute its anticonvulsant effect to a 
specific action at a sites. 
Given the unique profile of DTG in a variety of experimental systems, 
pharmacologic effects of DTG independent of its activity at a sites are not uncommon. In 
this context, the high affmity of DTG for a binding sites can only be considered a small 
part of the diverse and largely unexplored pharmacology of this interesting compound. A 
better understanding of the mechanism by which DTG exerts its potent and efficacious 
anticonvulsant effect in the prepiriform cortex will be of future importance. 
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Abstract 
Dextrorphan and dextromethorphan elicit a stereotyped behavioural syndrome in 
rats that is indistinguishable from that produced by PCP and other noncompetitive NMDA 
antagonists. The rank order of potency for the induction of stereotyped behaviour was 
MK-801 > PCP > (±)cyclazocine > dextrorphan > ketamine > dextromethorphan. These 
behavioural potencies were significantly correlated (0.94; P > 0.01) with their respective 
affinities for the high affinity [3H]dextrorphan binding site in rat forebrain membranes. To 
specifically address the propensity of dextromethorphan to induce adverse behavioural 
effects, dextrorotatory-opioid induced stereotypies were investigated in the female Dark 
Agouti and female Sprague-Dawley rats. The female Dark Agouti rat lacks cytochrome 
P450 2D1 which catalyses the 0-demethylation of dextromethorphan to dextrorphan. 
There were no differences in either the potencies or time to peak effect of dextrorphan and 
dextromethorphan to induce stereotyped behaviour in either of the two rat strains. These 
data suggest that the affinity of dextromethorphan for NMDA receptors adequately accounts 
for its ability to induce stereotyped behaviour. Following dextrorphan administration 
female Dark Agouti rats showed a greater incidence of stereotyped behaviour than Sprague-
Dawley rats, which may be indicative of strain differences in dextrorphan metabolism. In 
addition, dextrorotatory opioids were more potent inducers of stereotyped behaviour in 
female than male Sprague-Dawley rats. The commonality between the pharmacologic 
profiles of these compounds suggests that the abuse potential of dextromethorphan 
containing antitussive preparations is related to the noncompetitive NMDA antagonist 
activity of dextromethorphan and its primary metabolite dextrorphan. 47 
Introduction
 
The dextrorotatory opioids, dextrorphan and its 3-methyl ether derivative 
dextromethorphan, have virtually no affinity for opioid receptors and thus lack the potent 
analgesic properties, respiratory depressant effects and morphine-like addictive potential 
associated with related levorotatory opioid isomers (Isbell and Fraser, 1953). A number of 
opioids possess antitussive efficacy and it is this property that is responsible for the long 
and widespread use of dextromethorphan as a non-prescription cough suppressant in over 
sixty countries (Bern and Peck, 1992). Although devoid of morphine-like effects and 
consequently considered non-addictive (Isbell and Fraser, 1953), the dextrorotatory 
morphinans, at levels exceeding the recommended antitussive dose, can induce a 
phencyclidine (PCP)-like syndrome presumably by virtue of their activity as 
noncompetitive antagonists of the NMDA (N-methyl-D-aspartate) subfamily of ionotropic 
glutamate receptors. 
The numerous reports of recreational dextromethorphan abuse provide an early 
indication of a common pharmacologic basis of action for dextrorotatory opioids and PCP-
like drugs (Degkwitz, 1964; McCarthy, 1971). In 1964 Degkwitz reported sedative-
hypnotic effects, slurred speech, pupillary dilation, sensory distortion, drunkenness and 
euphoria in patients following ingestion of 300 mg (approximately ten times the antitussive 
dose) of dextromethorphan. In a later study in humans, Jasinski et al. (1971) reported 
sedative-hypnotic and psychotomimetic effects in subjects following consumption of doses 
approximately eight times higher than the recommended antitussive dose, and also noted 
that the subjective response to dextromethorphan was clearly different to that of morphine. 
Furthermore, drug discrimination studies in a variety of species have suggested a common 
basis for the effects of dextrorotatory opioids and PCP-like compounds (Holtzman, 1980, 
1994; Her ling et al., 1981, 1983). This relationship was established electrophysiologically 
when dextrorphan and dextromethorphan were reported to be selective antagonists of N­
methylaspartate-induced excitation of spinal neurones (Church et al., 1985). 48 
We have recently identified high affinity [3H]dextrorphan binding sites in rat 
forebrain that appear to be localized to a site within the ion channel domain of the activated 
NMDA receptor (Franklin and Murray, 1992). Although dextrorphan is undoubtedly a 
potent and selective noncompetitive NMDA receptor antagonist, the pharmacologic profile 
of dextromethorphan has remained less clear. Dextromethorphan has been suggested to be 
prototypical of a unique class of anticonvulsants that interact with high affinity at a site 
labelled by [3H]dextromethorphan (Tortella et al., 1988; 1994). The high affinity of 
dextromethorphan for both [3H]dextromethorphan binding sites (Craviso and Musacchio, 
1982b) and at sigma recognition sites (Walker et al., 1990) are pharmacologic 
characteristics that are thought to be unrelated to the activity of dextromethorphan at NMDA 
receptors. This distinctive dextromethorphan pharmacology is not shared by dextrorphan, 
which is consistently the more potent of the two compounds in many experimental models 
of NMDA receptor antagonism. Such studies include the ability of dextrorotatory 
morphinans to attenuate hypoxic injury in neuronal cultures (Goldberg et al., 1987) 
antagonize epileptiform activity (Wong et al., 1988; Aram et al., 1989) and protect against 
seizures in vivo (Leander et al., 1988; Tortella et al., 1988; Chapman and Meldrum, 1989; 
Roth et al., 1992). However, the rapid metabolism of dextromethorphan following 
systemic administration confounds the interpretation of many studies of the effects of 
dextromethorphan in vivo.  Of particular relevance to the present study, adverse 
behavioural effects of dextromethorphan have been attributed solely to the presence of its 
main metabolite dextrorphan, with the parent compound considered to be devoid of PCP-
like psychotomimetic effects (Szekely, 1991; Loscher et al., 1994). 
Dextromethorphan is metabolized via two different pathways: 0-demethylation to 
dextrorphan and N-demethylation to methoxymorphinan as shown in figure 4.1. Plasma 
and urine analysis following dextromethorphan administration in a variety of species 
indicates that of these two metabolic pathways, conversion to dextrorphan represents the FIGURE 4.1.
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predominant route (Kamm et al., 1967; Ramachander et al., 1977; Barnhart, 1980; Fossati 
et al., 1993). Dextrorphan may be excreted in its conjugated form or N-demethylated to 3­
hydroxymorphinan. In addition, 3-hydroxymorphinan can be formed by 0-demethylation 
of methoxymorphinan (Figure 4.1). The 0-demethylation of dextromethorphan is well 
characterized in humans and, like the antihypertensive debrisoquine, is catalysed by the 
polymorphic cytochrome P450 enzyme 2D6 (Cholerton et al., 1992). Cytochrome 
P4502D6 polymorphism in humans is genetically determined; infact, dextromethorphan is 
considered a safe probe for identifying poor metabolizers (PM) and extensive metabolizers 
(EM) of P4502D6 substrates in human populations (Kupfer et al., 1986). In rodents, 
female Dark Agouti and female Sprague-Dawley rats have been shown to be suitable animal 
models for the study of human PM and EM phenotypes respectively (Al-Dabbagh et al., 
1980; Zysset et a., 1988). The female Dark Agouti rat does not express CYP2D1 
(Matsunaga et al., 1989) and is consequently deficient in P4502D1 which catalyses the 0­
demethylation of dextromethorphan to dextrorphan in Sprague-Dawley rats (Figure 4.1). 
The aim of the present study was to investigate the ability of dextrorphan and 
dextromethorphan to induce stereotyped behaviour in the rat. We have assessed the 
propensity of the dextrorotatory morphinans and other noncompetitive NMDA antagonists, 
including MK-801 and PCP, to induce stereotypies in male Sprague-Dawley rats and 
compared the rank order of potency of these compounds with their respective affinities for 
the high-affinity [3H]dextrorphan binding site in rat forebrain membranes (Franklin and 
Murray, 1992). To further investigate dextrorotatory-induced stereotypies and to 
specifically address the propensity of dextromethorphan to induce these behaviours, we 
have compared the effects of these compounds in female Sprague-Dawley and female 
P4502D1 deficient Dark Agouti rats.  In addition, the ability of dextrorphan and 
dextromethorphan to impair motor coordination was also assessed in both rat strains. 51 
Materials and Methods 
Animals 
Male Sprague-Dawley rats (180-230 g) were purchased from Simonsen 
Laboratories, Gilroy, CA. Female Dark Agouti rats (150-170 g) and female Sprague-
Dawley rats (160-200 g) were purchased from Bantin and Kingman, Fremont, CA. 
Animals were housed in groups of four to six at 22°C on a standard 12 hour light-dark 
schedule. Food and water were available ad libitum. Animals were allowed to acclimatize to 
the test room for at least one hour prior to an experimental session and were only used 
once.  All testing was took place between 1 p.m. and 7 p.m. each day. Effects of 
dextrorotatory opioids in female Dark Agouti and female Sprague-Dawley rats were always 
studied in pairs of animals (one of each strain) that had been weight-matched as closely as 
possible. 
Drugs. 
Dextrorphan, MK-801, ketamine and dextromethorphan were purchased from 
Research Biochemicals International (Antic, MA). PCP and (±)cyclazocine were provided 
by the National Institute on Drug Abuse. All compounds were dissolved in deionized 
water with the exception of (±)cyclazocine which was dissolved in a small volume of 0.1N 
HC1, diluted with deionized water and the pH adjusted to 6.0 with 0.5N NaOH. All drug 
solutions were administered i.p. in a constant injection volume of 5m1/kg. 
Evaluation of Stereotyped Behaviour. 
This procedure has been described in detail elsewhere (Murray and Horita, 1979). 
Briefly, following i.p. injection of vehicle (control) or drug solution (test) animals were 
immediately transferred into large, individual Plexiglass testing chambers and observed for 
2 hours. The presence or absence of any of the following three stereotyped behaviours 
was recorded during a one minute epoch every five minutes: (1) Repetitive lateral head 52 
swaying, (2) Circling (pivoting around the hind limbs in either direction) and (3) Backward 
walking (involving all four limbs). The total incidence of each behaviour was determined 
for each animal over the two hour observation period. Mean total stereotypy scores were 
calculated for each dose group by summing the scores for the three individual behaviours. 
Evaluation of Rotorod Performance. 
Animals were trained one to two hours before the experimental session to remain on 
a rotating rod of 7 cm diameter, rotating at 6 revolutions per minute. Rats were allowed 
three practice trials, after which all animals were able to remain on the rotorod for at least 
60 sec. Animals were injected with deionized water, dextrorphan or dextromethorphan and 
returned to their individual cages. Thirty minutes post-injection (dextrorphan or control) or 
forty-five minutes post-injection (dextromethorphan or control), animals were placed on the 
rotating rod. Animals that were unable to remain on the rotating rod for a 60 sec testing 
period were considered to have failed the rotorod test. 
Data Analysis. 
Dose-response data were analyzed by iterative non-linear least squares regression 
analysis to generate a sigmoid curve defined by the following four parameter logistic 
equation: 
E =  E. 
1 + (ED50 1 [D])" 
where E = response, E  = maximal response, D = dose and n = a slope factor. 53 
Results 
The stereotyped behavioural syndrome elicited by dextrorphan and 
dextromethorphan in male Sprague-Dawley rats was indistinguishable from that produced 
by MK-801, PCP, (±)cyclazocine and ketamine. Control animals treated with deionized 
water or vehicle failed to show stereotyped behaviour. As shown in figure 4.2, all 
compounds induced stereotypies in a dose-dependent manner. Although there was a dose-
dependent increase in all three behaviours, repetitive lateral head swaying was the 
predominant stereotypy, followed by circling which was more common than backward 
walking at all dose levels. Ketamine-treated rats showed varying degrees of ataxia at doses 
of 60 mg/kg and above, whilst dextromethorphan induced convulsions in 1 rat at 60 mg/kg 
and 2 rats at 100 mg/kg. Both these conditions impaired the ability of animals in these dose 
groups to perform stereotyped or normal behaviours, thereby influencing the total 
stereotypy score. Differences in drug disposition over the two hour observation period 
may also contribute to the seemingly limited efficacy of some of these compounds. 
The rank order of potency for induction of stereotyped behaviour was: MK-801 > 
PCP > (±)cyclazocine > dextrorphan > ketamine > dextromethorphan (Table 4.1). The 
correlation between the potencies of these compounds to induce stereotyped behaviour and 
their respective affinities as inhibitors of high- affinity [3H]dextrorphan binding in rat 
forebrain membranes is shown in figure 4.3. Linear regression of the log transformed data 
gave a correlation coefficient of 0.937 (P > 0.01). These data suggest that the ability of 
these compounds to act as noncompetitive NMDA antagonists appears to underlie their 
ability to elicit stereotyped behaviour in these animals. 
The rapid metabolism of dextromethorphan to dextrorphan is a complicating factor 
in the interpretation of many in vivo studies investigating the noncompetitive NMDA 
antagonist activity of dextromethorphan. In order to study dextrorotatory opioid-induced 
stereotypies under conditions of enhanced dextromethorphan bioavailability, the 
behavioural effects of these compounds in female Sprague-Dawley rats and cytochrome 54 
FIGURE 4.2.
 
Dose response relationships for MK-801, PCP, (±)cyclazocine, ketamine,
 
dextrorphan (DX) and dextromethorphan (DXM)-induced stereotyped
 
behaviour in male Sprague-Dawley rats.
 
Following i.p. administration of a test compound rats were placed in an open field arena 
and observed for 2 hours. The presence or absence of repetitive lateral head swaying, 
circling and backward walking was recorded during a 1 min epoch every 5 min. Symbols 
represent mean total stereotypy scores at each dose group (n = 4 animals) and the respective 
curves are expanded from the parameter estimates derived from fitting a logistic equation to 
the data by means of iterative nonlinear least squares regression analysis. 
FIGURE 4.3. 
Correlation between the potencies of noncompetitive antagonists to induce 
stereotyped behaviour in male Sprague-Dawley rats and their respective 
affinities for the high-affinity [3H]dextrorphan binding site in rat forebrain 
membranes. 
The potencies (i.unol) of MK-801, PCP, (±)cyclazocine, ketamine, dextrorphan (DX) and 
dextromethorphan (DXM) to induce stereotyped behaviour in male Sprague-Dawley rats 
were highly correlated (r = 0.937; p < 0.01) with their respective affinities as inhibitors of 
high-affinity [3H]dextrorphan binding in rat forebrain membrane preparations. IC50 values 
(nM) taken from Franklin and Murray (1992), except (±)cyclazocine (unpublished data). 
The significance of the correlation was evaluated by t test of the probability of r:). 55 
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TABLE 4.1. 
Potencies of noncompetitive NMDA antagonists to induce stereotyped 
behaviour in male Sprague-Dawley rats 
Compound  ED50 ± S.E. 
mg/kg  gmol/kg I 
MK-801  0.3 ± 1.1  0.89 
PCP  7.0 ± 1.1  25 
(±)Cyclazocine  20.1 ± 16.1  74 
Dextrorphan  82.7 ± 1.2  203 
Ketamine  62.2 ± 1.2  227 
Dextromethorphan  103 ± 1.0  291 
Rats were injected i.p. with a single dose of the appropriate test compound 
immediately before being placed in an open field arena. The presence or absence of 
repetitive lateral head swaying, circling and backward walking was recorded during a 
1 min epoch every 5 min over a 2 hour observation period. Group mean stereotypy 
scores were calculated for each dose by summing the scores  of the 3 individual 
behaviours (n= 4 animals). 58 
P450 2D1 deficient female Dark Agouti rats were compared. As shown in figure 4.4, 
dextrorphan and dextromethorphan induced stereotyped behaviour in female Dark Agouti 
rats and female Sprague-Dawley rats in a dose-dependent manner. As noted for male 
Sprague-Dawley rats, repetitive lateral head swaying was the predominant stereotypy in 
both rat strains. Control animals treated with deionized water failed to show stereotyped 
behaviour. Both compounds were more potent inducers of stereotypies in female animals 
than in male Sprague-Dawley rats, however, there were no differences in the potencies of 
dextrorphan or dextromethorphan to elicit stereotyped behaviour in either of the female rat 
strains (Table 4.2 ).  Although dextrorphan was equipotent in its ability to induce 
stereotypies in both rat strains, Dark Agouti rats showed a significantly greater incidence of 
stereotyped behaviour at higher doses (45 and 60 mg/kg) (Figure 4.4). 
TABLE 4.2. 
Potencies of dextrorphan and dextromethorphan to induce stereotyped 
behaviour in female Sprague-Dawley and female Dark Agouti rats 
Sprague Dawley  Dark Agouti 
ED50 ± S.E.  ED50 ± S.E. 
Compound  mg/kg  gmol/kg  mg/kg  gmol/kg 
Dextrorphan  44.0 ± 1.1  108  40.0 ± 1.0  98 
Dextromethorphan  55.0 ± 1.1  157  52.0 ± 1.0  148 
Rats were injected i.p. with a single dose of dextrorphan or dextromethorphan 
immediately before being placed in an open field arena. The presence or absence of 
repetitive lateral head swaying, circling and backward walking was recorded during a 
1 min epoch every 5 min over a 2 hour observation period. Group mean stereotypy 
scores were calculated for each dose by summing the scores of the 3 individual 
behaviours (n = 4-6 animals) 59 
FIGURE 4.4.
 
Dose response relationships for dextrorphan and dextromethorphan-induced
 
stereotyped behaviour in female Dark Agouti and female Sprague-Dawley
 
rats.
 
Following i.p. administration of a test compound, rats were placed in an open field arena 
and the presence or absence of repetitive lateral head swaying, circling and backward 
walking was recorded during a 1 min epoch every 5 min. Values represent mean total 
stereotypy scores at each dose group (n = 46 animals) over a 2 hour observation period. * 
Mean total stereotypy score was significantly different from Sprague-Dawley dose group 
(Student's t test, P < 0.01). FIGURE 4.4.
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The duration of dextrorotatory opioid-induced stereotyped behaviour was a function 
of dose. As shown in figure 4.5, the peak effect of dextrorphan occurred during the 20 to 
30 min epochs, with the intensity and duration of the animal's behaviour being more 
prolonged following a 60 mg/kg dose (lower panel). The peak effect of dextromethorphan­
induced stereotypies was the same in female Dark Agouti and female Sprague-Dawley rats 
and occurred during the 35 to 45 min epochs (figure 4.6). After an initial rise, the transient 
decline in stereotyped behaviour in both rat strains 20 to 30 min following a 60 mg/kg dose 
of dextromethorphan (lower panel) was a direct result of the ability of dextromethorphan to 
induce convulsions in the majority of animals at this dose level, and thus impair their 
capacity to perform other behaviours. Total stereotypy scores increased at later time points 
following a short recovery period. Dark Agouti rats continued to display stereotyped 
behaviour 120 min post-injection (60 mg/kg). 
To further assess the adverse behavioural effects of these compounds, the ability of 
dextrorphan and dextromethorphan to disrupt motor coordination was studied in female 
Dark Agouti and female Sprague-Dawley rats.  Dextrorphan and dextromethorphan, 
measured 30 and 45 min post-injection respectively, impaired rotorod performance in a 
dose-dependent manner in both rat strains (Figure 4.7). Dextrorotatory opioids were more 
potent in their ability to disrupt motor coordination than induce stereotyped behaviour in all 
test groups with the exception of the effects of dextromethorphan in female Sprague-
Dawley rats (Table 4.3). Dextrorphan was more potent than dextromethorphan in its ability 
to disrupt rotorod performance. In addition, both dextrorphan and dextromethorphan were 
more potent in their ability to impair rotorod performance in female Dark Agouti rats than in 
female Sprague-Dawley rats (Table 4.3 ). 62 
FIGURE 4.5.
 
Time course of stereotyped behaviour induced by 45 mg/kg and 60 mg/kg
 
doses of dextrorphan in female Sprague-Dawley and female Dark Agouti
 
rats.
 
Following i.p. administration of dextrorphan, 45 mg/kg (upper panel) and 60 mg/kg (lower 
panel), rats were placed in an open field arena and the presence or absence of repetitive 
lateral head swaying, circling and backward walking recorded during a 1 min epoch every 
5 min. Values represent total stereotypy scores (n = 5 animals) over a 2 hour observation 
period. 
FIGURE 4.6.
 
Time course of stereotyped behaviour induced by 45 mg/kg and 60 mg/kg
 
doses of dextromethorphan in female Sprague-Dawley and female Dark
 
Agouti rats.
 
Following i.p. administration of dextromethorphan, 45 mg/kg (upper panel) and 60 mg/kg 
(lower panel), rats were placed in an open field arena and the presence or absence of 
repetitive lateral head swaying, circling and backward walking recorded during a 1 min 
epoch every 5 min. Values represent total stereotypy scores (n = 6 animals) over a 2 hour 
observation period. 63 
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FIGURE 4.7.
 
Ability of dextrorphan and dextromethorphan to impair rotorod performance
 
in female Sprague-Dawley and female Dark Agouti rats.
 
Dose response relationships showing the ability of dextrorphan (upper panel) and 
dextromethorphan (lower panel) to impair rotorod performance in female Sprague-Dawley 
and female Dark Agouti rats. Performance was evaluated 30 min (dextrorphan) or 45 min 
(dextromethorphan) following i.p. administration of the test compound. Percent failure 
indicates % of animals in each dose group (n = 3-4) failing to remain on the rotorod for 60 
sec. 66 
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TABLE 4.3.
 
Potencies of dextrorphan and dextromethorphan to impair rotorod 
performance in female Sprague-Dawley and female Dark Agouti rats 
Sprague Dawley  Dark Agouti 
ED50 ± S.E.  ED50 ± S.E. 
Compound  mg/kg  1.1mol/kg  mg/kg  limo 1/kg 
Dextrorphan  32.0 ± 3.0  79  16.0 ± 1.6  39 
Dextromethorphan  52.0 ± 1.0  148  25.0 ± 1.2  71 
Rotorod performance was evaluated 30 min (dextrorphan) or 45 min 
(dextromethorphan) following i.p. administration of the test compound. Percent failure 
was calculated for each dose group (n = 3-4 animals) as the % of animals failing to 
remain on the rotorod for 60 sec. 
Discussion 
The ability of PCP to produce a characteristic and reproducible stereotyped 
behavioural syndrome in rats has been known for some time (Murray and Horita, 1979). 
Other noncompetitive NMDA antagonists, including dextrorphan and dextromethorphan, 
have also been shown to produce PCP-like effects in laboratory rodents and other species 
(Murray et al., 1982; Koek et al., 1988; Skekely et al., 1991).  In the present study 
dextrorphan and dextromethorphan induced a stereotyped behavioural syndrome in rats that 
was indistinguishable from that produced by MK-801 and PCP. This dextrorotatory 
opioid-induced hyperactivity was characterized by repetitive head swaying, with circling 
and backward walking occurring at higher doses. Furthermore, the potencies of an array 
of noncompetitive NMDA antagonists to produce these behaviours were significantly 
correlated with their respective affinities as inhibitors of high affinity [3H]dextrorphan 68 
binding to rat forebrain membrane preparations (Franklin and Murray, 1992). The ability 
of these compounds to act as noncompetitive NMDA antagonists therefore appears to 
underlie their propensity to produce stereotyped behaviour in rats. 
The finding that dextrorphan was more potent than dextromethorphan in these 
studies is consistent with radioligand binding data. Dextrorphan is more potent than 
dextromethorphan as an inhibitor of [3H]PCP binding (Murray and Leid, 1984) and 
[311]dextrorphan binding (Franklin and Murray, 1992) to rat brain membranes. Although 
these data strongly suggest that interaction with NMDA receptors mediates the observed 
psychoactive properties of the dextrorotatory morphinans, the well documented 0­
demethylation of dextromethorphan to dextrorphan (Figure 1) is a confounding factor in the 
interpretation of the effects of dextromethorphan in vivo. The results of our studies with 
female Dark Agouti rats, however, indicate that dextromethorphan also has psychoactive 
properties. 
There was no difference in the potency of dextromethorphan to induce stereotyped 
behaviour in female Dark Agouti and female Sprague-Dawley rats. Furthermore, over a 
two hour observation period dextromethorphan showed the same time to peak effect in both 
rat strains. Presumably if dextromethorphan had to first be metabolized to dextrorphan in 
order to induce its effect, the onset of stereotyped behaviour would be different for the 
Dark Agouti group.  It therefore appears that the stereotyped behavioural response 
observed in female Dark Agouti rats is induced by dextromethorphan. Metabolic fate 
studies conducted both in vitro in liver microsomes (Zysset et al., 1988; Kerry et al., 1993) 
and in vivo (Zysset et al., 1988; Bochner et al., 1994) indicate that the clearance rate of 
dextromethorphan is greatly reduced in the female Dark Agouti rat compared to the female 
Sprague-Dawley. Consistent with these observations, Dark Agouti rats excrete a greater 
percentage of unchanged dextromethorphan 48 hours ( Bochner et al., 1994) or 72 hours 
(Zysset et al., 1988) after administration of the parent compound than Sprague-Dawley 
rats. As a compensatory mechanism the N-demethylation of dextromethorphan, which is a 69 
mediated by different cytochrome P450 enzymes and thought to be a minor pathway in the 
Sprague-Dawley rat, appears to be increased in the Dark Agouti strain (Kerry et al., 1993). 
Consequently, a larger percentage of the total recovered dose is excreted as 3­
methoxymorphinan in the Dark Agouti rat (Zysset et al., 1988; Bochner et al., 1994). 
Alternative 0-demethylation pathways are also likely to compensate for the absence of 
P4502D1 in the female Dark Agouti rat. However, based on the study of debrisoquine 
metabolizing P450s, it has been suggested that other enzymes probably have reduced 
affinity for P4502D1 substrates in vivo (Matsunaga et al., 1989). It is therefore assumed 
that alternative pathways do not make a significant contribution to the formation of 
dextrorphan in female Dark Agouti rats over the time course of our studies. 
Dextrorphan was also equipotent in its ability to induce stereotypies in female Dark 
Agouti and Sprague-Dawley rats, yet the Dark Agouti rats showed a significantly greater 
incidence of stereotyped behaviour at the higher doses tested.  In vitro studies have 
indicated that there are no differences between the two rat strains with respect to the N­
demethylation of dextrorphan (Kerry et al., 1993). It is possible therefore that the two 
strains differ in their ability to perform glucuronide conjugation reactions even though this 
appears not to be the case in humans. Duch6 et al. (1993) recently reported that 
dextrorphan was normally glucuronidated in a population of poor metabolizers. However, 
given the wide species variation in drug metabolizing enzymes, this finding does not 
necessarily apply to the female Dark Agouti rat. It has been proposed that sex-dependent 
differences in glucuronidation may account for the striking differences observed in the 
pharmacokinetics of dextrorphan in male and female Sprague-Dawley rats. Ramachander 
et al. (1978) noted that following oral administration of dextromethorphan, the plasma half-
life of dextrorphan in male rats was approximately half that observed in females. This 
appears not to be the case in human populations; no sex-dependent differences were 
observed in the pharmacokinetics of dextromethorphan and dextrorphan in poor and 
extensive metabolizers (Kuppfer et al., 1986). Given the observations by Ramachander et 70 
al. (1978), enhanced bioavailability may explain the increased potency of the dextrorotatory 
opioids to induce stereotyped behaviour in female rats compared to male rats reported 
herein. 
The spectrum of behavioural effects observed following administration of a 
noncompetitive NMDA antagonist is clearly dose-dependent (Murray, 1994). It is not 
surprising, therefore, that motor coordination was impaired by dextrorphan and 
dextromethorphan in both rat strains. In particular, the ability of dextromethorphan to 
potently diminish rotorod performance in female Dark Agouti rats lends further support for 
NMDA receptor-mediated adverse behavioural effects of dextromethorphan. Moreover, the 
propensity of dextrorphan to markedly impair motor coordination in female Dark Agouti 
rats is consonant with a possible difference in the ability of this strain to metabolize 
dextrorphan. In the Sprague-Dawley rat, dextrorphan is largely excreted in its conjugated 
form following i.p. administration of dextrorphan (Bochner et al., 1994). Unfortunately, 
these authors did not compare the metabolic fate of dextrorphan in Dark Agouti and 
Sprague-Dawley rat strains following dextrorphan administration . 
The results of the present study suggest that the affinity of dextromethorphan for 
NMDA receptors can adequately account for its propensity to induce stereotyped behaviour 
in the rat.  These data are in agreement with numerous studies of the effects of 
dextromethorphan in vitro where metabolism to dextrorphan is not a confounding factor in 
the interpretation of the noncompetitive NMDA antagonist activity of dextromethorphan 
(Goldberg et al., 1987; Wong et al., 1988; Aram et al., 1989). Studies of the effects of 
dextromethorphan in vivo, that have been designed to limit metabolite formation, also 
demonstrate that noncompetitive antagonism of NMDA receptors mediates the behavioural 
effects of dextromethorphan. Holtzman (1994) recently reported that the discriminative 
stimulus effects of s.c. dextromethorphan are clearly PCP-like and not mediated by the 
high affinity [3H]dextromethorphan binding site.  Furthermore, in a study of the 
therapeutic efficacy of dextromethorphan in humans, patients were given the selective 71 
cytochrome P4502D6 inhibitor quinidine to inhibit dextromethorphan metabolism and thus 
enhance its bioavailability (Zhang et al., 1992). High plasma concentrations of 
dextromethorphan were not well tolerated by all patients; one patient experienced a severe 
PCP-like reaction following a 60 mg oral dose in the presence of 150 mg/day quinidine. 
Other patients who failed to complete the drug trial complained of adverse side effects such 
as nervousness, tremors, fatigue, unsteady gait, dizziness and confusion (Zhang et al., 
1992). 
In summary, dextrorphan and dextromethorphan produced a stereotyped 
behavioural response in rats that was indistinguishable from that produced by PCP and 
other noncompetitive NMDA antagonists. The correlation of this pharmacologic profile 
with that defined by [3H]dextrorphan equilibrium competition binding studies suggests that 
interaction with the NMDA receptor - channel complex mediates the stereotyped behavioural 
effects of these compounds. Dextromethorphan was equipotent in its ability to induce 
stereotypies in female Dark Agouti and female Sprague-Dawley rats. Moreover, following 
dextromethorphan administration there was no difference in the time to peak effect between 
the two rat strains. Together, these results suggest that the affmity of dextromethorphan 
for NMDA receptors adequately accounts for its propensity to induce stereotyped 
behaviour. Although dextromethorphan has a distinct pharmacology that is thought to be 
unrelated to its activity as an NMDA receptor antagonist and may explain some of its effects 
in vivo (Torte lla et al., 1988, 1994; Szekely, 1991; Loscher and Honack, 1993), it would 
be premature to consider it completely devoid of the adverse behavioural effects associated 
with noncompetitive NMDA antagonists. 
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Abstract 
The pharmacologic specificity and anatomical distribution of [3H]dextrorphan 
recognition sites in the rat brain was characterized by quantitative autoradiography. 
Equilibrium saturation analysis indicated that [3H]dextrorphan labelled a single population 
of high affinity binding sites. These sites are heterogeneously distributed throughout rat 
forebrain with the following order of binding densities: hippocampal formation > cerebral 
cortex > thalamic nuclei > striatum. The association rate of [3H]dextrorphan with its 
binding site in area stratum radiatum of CA1 is accelerated by the addition of glycine and 
glutamate. [3H]Dextrorphan binding is, however, relatively insensitive to glycine and 
glutamate under equilibrium conditions, despite extensive pre-washing procedures to 
deplete endogenous levels of these substances. The competitive N-methyl-D-aspartate 
(NMDA) antagonist D(-)-2-amino-5-phosphonopentanoic acid (D-AP5) and the glycine site 
antagonist 7-chlorokynurenic acid completely inhibit specific [3H]dextrorphan binding. D­
APS suppresses [3H]dextrorphan binding in a regionally distinctive manner; a population 
of binding sites is weakly inhibited by D-AP5 in the lateral thalamic nuclei, whereas D-AP5 
potently inhibits [3H]dextrorphan binding in the cerebral cortex. The rank order of 
potencies of an array of noncompetitive antagonists to inhibit [3H]dextrorphan binding 
unambiguously displays the pharmacologic profile of the noncompetitive antagonist domain 
of the NMDA receptor-channel complex. Furthermore, the distribution of [3H]dextrorphan 
binding sites in slide-mounted tissue is in excellent agreement with the distribution of 
NMDA receptors previously reported using NMDA-displacement of [3H] glutamate, 
[3H] (+)-5-methy1-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) and 
[3H]1 -[1-(2-thienyl)cyclohexyl]piperadine (TCP). An exception was the molecular layer of 
the cerebellum, where the density of [3H]dextrorphan binding sites was particularly high. 
The regional distribution of [3H]dextrorphan binding sites in rat brain does not correspond 
to the reported distributions of [3H]dextromethorphan or sigma binding sites. 74 
Introduction 
Dextrorphan, (+)-3-hydroxy-N-methyl-morphinan, is a selective noncompetitive 
antagonist of the NMDA (N-methyl-D-aspartate) subfamily of ionotropic glutamate 
receptors. Dextromethorphan, the 3-methyl derivative of dextrorphan, which has found 
widespread use as a non-prescription antitussive is also an effective noncompetitive NMDA 
antagonist but is less potent than dextrorphan in a variety of experimental models of NMDA 
receptor antagonism. These studies document the activity of dextrorotatory morphinans to 
attenuate hypoxic injury in neuronal cultures (Goldberg et al., 1987), antagonize 
epileptiform activity (Wong et aL, 1988; Aram et al., 1989) and protect against seizures in 
vivo (Leander et al., 1988; Chapman and Meldrum, 1989; Roth et al., 1992). 
Ionotropic glutamate receptors have traditionally been subclassified according to 
pharmacologic criteria: the NMDA receptors, which are activated by the agonist NMDA, 
and the non-NMDA receptors, which include those receptors sensitive to the agonists a-
amino-3-hydroxy-5-methy1-4-isoxazolepropionic acid (AMPA) and kainate (Monaghan et 
al., 1989; Watkins et al., 1990). With respect to its pharmacology and physiology, the 
NMDA receptor-channel complex is the most thoroughly characterized of the glutamate 
receptors and appears to have several distinguishing features. The NMDA receptor channel 
is highly permeable to Ca2+, has an NMDA agonist recognition site, a strychnine 
insensitive glycine co-agonist site, is blocked by Mg2+ in a voltage-dependent manner and 
also has binding sites for Zn2+ and polyamines.  Finally, and most germane to the 
pharmacology of dextrorphan, the activated NMDA receptor is noncompetitively blocked 
by a structurally diverse group of compounds that are thought to bind within the ion 
channel.  These  compounds  include  (+)-5-methy1-10,11-dihydro-5H­
dibenzo[a,d]cyclohepten-5,10-imine (MK-801), dissociative anaesthetics, phencyclidine 
(PCP) and ketamine, dextrorotatory morphinans, dextrorphan and dextromethorphan, and 
benzomorphans such as cyclazocine and N-allylnormetazocine (SKF 10,047). 75 
Early reports of recreational dextromethorphan abuse (Degkwitz, 1964; McCarthy, 
1971) provided an indication of a common pharmacologic basis for the effects of the 
dextrorotatory morphinans and PCP-like drugs. Furthermore, the results of many drug 
discrimination studies have suggested a common mode of action for the effects of 
dextrorphan and PCP-like compounds. Dextrorphan will substitute for PCP (Holtzman, 
1980), ketamine ( Herling et al., 1981), dextromethorphan (Holtzman, 1994), cyclazocine 
(Teal and Holtzman, 1980; Her ling et al., 1981) and SKF 10,047 (Shannon, 1983) in a 
variety of species. Similarly, dextromethorphan, cyclazocine and SKF 10,047 produce 
dose-dependent dextrorphan-appropriate responses in animals trained to discriminate 
dextrorphan from saline (Her ling et al., 1983). The relationship between these compounds 
was established electrophysiologically when dextrorphan, like PCP and ketamine (Anis et 
al., 1983), was reported to be a selective antagonist of N-methylaspartate-induced 
excitation of spinal neurones (Church et al.., 1985). Dextromethorphan also selectively 
antagonized N-methylaspartate-induced excitation but was 5-fold less potent than 
dextrorphan (Church et al., 1985). Dextromethorphan, in addition, is thought to be 
prototypical of a unique class of anticonvulsants acting through a site labelled by 
[3H]dextromethorphan (Tortella et al.,  1988; 1994).  The high affinity of 
dextromethorphan for both [3H]dextromethorphan binding sites (Craviso and Musacchio, 
1983b) and the sigma-1 recognition site (Walker et al., 1990) represent features that are 
unique to dextromethorphan, these pharmacologic characteristics are not shared by 
dextrorphan and are thought to be unrelated to the activity of dextromethorphan as an 
NMDA receptor antagonist. 
The NMDA receptor appears to be composed of several subunits which co­
assemble to form a functional channel. Two families of NMDA receptor subunits have 
recently been cloned and termed NMDAR1 (NR1) and NMDAR2 (NR2) in rat brain 
(Moriyoshi et al., 1991; Monyer et a1.,1992; Ishii et al, 1993), and designated  and c in 
mouse brain (Yamazaki et al., 1992; Ikeda et a1.,1992; Meguro et al., 1992; Kutsuwada et 76 
al., 1992). Eight different isoforms generated by alternative splicing of mRNA have been 
identified for the NR1 subunit (Sugihara et al.., 1992; Nakanishi. et al., 1992; Hollman et 
al., 1993), whereas the NR2 family currently consists of four closely related subunits 
termed NR2A-NR2D (Monyer et al., 1992; Ishii et al., 1993). Although the NR1 subunit 
is able to form functional homo-oligomeric receptors (Moriyoshi et al., 1991), co­
expression of NR1 with an NR2 subunit greatly potentiates responses to glutamate or 
NMDA and produces functional variability depending on the subunit combination (Meguro 
et al., 1992; Kutsuwada et al., 1992; Monyer et al., 1992; Ishii et al., 1993). Localization 
of mRNA for NR1 by in situ hybridization techniques reveals an abundant and ubiquitous 
expression throughout the rat brain (Moriyoshi et al., 1991.), that is in marked contrast to 
the distinctive and restricted distribution of mRNA for NR2 subunits (reviewed in 
Nakanishi, 1992). The potential for regional and functional NMDA receptor heterogeneity 
has now been further extended by the recent fmdings of Laurie and Seeburg (1994a). 
Using in situ hybridization techniques to detect the location of mRNA for the eight possible 
forms of the NR1 subunit these authors reported that although some splice forms occur 
extensively and homogeneously in the adult rat brain, the occurrence of other splice forms 
is restricted to specific brain regions. 
In order to determine the functional significance of various combinations of 
recombinant NMDA receptor subunits and splice variants, there is an increasing need for a 
better understanding of the regional distribution and properties of native NMDA receptors. 
Receptor autoradiography has already provided some evidence for regionally 
heterogeneous populations of native NMDA receptors in the rat forebrain based on 
differential activation of the NMDA receptor-channel complex by [3H]glutamate, binding of 
the competitive glutamate antagonist [311]3-(2-carboxypiperazin-4-y1)-propy1-1-phosphonic 
acid ([3H]CPP) or regulation of [3H]MK -801 binding by NMDA receptor agonists and 
antagonists (Monaghan et al., 1988; Monaghan 1991; Beaton et al., 1992; Sakurai et al., 
1993). In addition, a pharmacologically distinct NMDA receptor has been identified in the 77 
cerebellum that appears to have, as one of its characteristics, a particularly low affinity for 
MK-801 (Maurice and Vignon 1990; Quarum et al., 1990; Ebert et a., 1991; Beaton et a, 
1992). Further support for NMDA receptor heterogeneity amongst native NMDA receptors 
of unknown subunit composition is provided by data derived from the study of 
recombinantly expressed heteromeric NMDA receptors. With respect to the pharmacology 
of noncompetitive antagonists of the NMDA receptor, differences in the characteristics of 
channel blockade (Kutsuwada et al., 1992; Lynch et al., 1993; Yamakura et al., 1993) and 
the binding affinity of [3H]MK -801 (Cik et al., 1993; Chazot et at, 1994; Laurie and 
Seeburg, 1994b) have been shown to vary as a function of subunit composition. 
Our previous studies indicate that [3H]dextrorphan labels a high affmity site in rat 
brain membranes corresponding to the noncompetitive antagonist binding domain of the 
activated state of the NMDA receptor-channel complex (Franklin and Murray, 1990; 
Franklin and Murray, 1992). Although [3H]dextrorphan appears to recognize an "open 
channel" binding domain approximating the site or sites of other specific noncompetitive 
NMDA antagonists, the binding domain of [3H]dextrorphan may not be identical to the 
channel binding sites of either [3H]MK -801 or [311]1-[1-(2-thienyl)cyclohexyl]piperidine 
([3H]TCP). Specific aspects of the regulation of [3H]dextrorphan binding by modulators 
of the NMDA receptor-channel complex distinguish it from [3H]MK -801 and [311]TCP and 
may be indicative of underlying differences in the mechanisms of noncompetitive 
antagonism among these compounds. [31-1]Dextrorphan may therefore represent a unique 
ligand for the NMDA receptor-channel complex that could facilitate the identification of 
functionally and regionally distinct populations of native NMDA receptors. 
In the present study we have defined a procedure for quantitative autoradiographic 
visualization of [3H]dextrorphan binding sites in slide-mounted sections and confirmed the 
specificity of this autoradiographic assay for the labelling of a site within the ion channel 
domain of the NMDA receptor. To gain further insight into the mechanism by which 
[3H]dextrorphan interacts with the NMDA receptor-operated cation channel,  we have 78 
specifically assessed the regulation of [3H]dextrorphan binding by glycine and glutamate in 
several brain areas.  In addition, we have studied the regional distribution of 
[3H]dextrorphan binding sites in the rat brain and compared the relative distribution with 
previously reported distributions determined by autoradiographic visualization of NMDA 
receptors. 
Materials and Methods 
Materials 
[3H]Dextrorphan (47.5 Ci/mmol) was provided by Dupont-New England Nuclear 
(Boston, MA).  Dextrorphan, MK-801, TCP, ketamine, dextromethorphan and 7­
chlorokynurenic acid were purchased from Research Biochemicals International (Natick, 
MA). D(-)-AP5 was purchased from Tocris Neuramin (Essex, U.K.). PCP was provided 
by the National Institute on Drug Abuse. 4-(2-hydroxyethyl)-1-piperazineethansulfonic 
acid (HEPES) hemisodium salt was purchased from Research Organics Inc. (Cleveland, 
OH). All other compounds were purchased from Sigma Chemical Co. (St. Louis, MO). 
Tissue preparation 
Male Sprague-Dawley rats (Simonsen Labs., Gilroy, CA; 250-350 g) were 
decapitated under CO2-induced narcosis.  Brains were rapidly removed, frozen by 
immersion in isopentane at -20°C and stored at -70 °C until use. Frozen brains were 
warmed sufficiently in a cryostat (Minotome, IEC) to allow them to be blocked and freeze-
mounted to brass microtome chucks with Tissue Tek (Miles, Elkhart, IN) embedding 
medium. Serial 16-1.tm sections were cut on the cryostat at -17°C and thaw-mounted onto 
gelatin-coated (0.5%; porcine 300 bloom) microscope slides.  Slide-mounted brain 
sections, two per slide, were desiccated at 4°C under vacuum for 24 h and then stored at 
-20°C for up to three weeks. 79 
Radioligand binding 
Slide-mounted sections were allowed to thaw at room temperature for 30-45 min. 
Sections were then pre-washed (3 x 20 min) in a large volume of 5 mM HEPES buffered to 
pH 7.4 at 20°C. In studies to investigate the effect of prolonged washing, sections were 
immersed in 5 mM HEPES at 4°C (pH 7.4) for 16 h prior to this procedure. Excess buffer 
was aspirated from each slide before allowing the sections to air dry; at this time each 
section was circumscribed by a barrier drawn with a wax pencil. [3H]Dextrorphan binding 
was routinely determined by covering each section with a droplet (430 Ill for coronal and 
sagittal sections or 480111 for horizontal sections) of 5 mM HEPES pH 7.4 containing 40 
nM [3H]dextrorphan, 100 µM glycine, 1 11M glutamate and 1 mM EDTA. Nonspecific 
binding was defined by the presence of 1001.1M MK-801 in adjacent brain sections. Under 
these conditions at 20°C the [3H]dextrorphan association reaction is >95% complete by 4 h. 
An H2O vapour-saturated environment was employed during the long incubation period in 
order to minimize droplet evaporation (approximately 1% after 8 h).  After routine 
incubation for 4 h, the reaction was terminated by draining the incubation droplets and 
rapidly dipping each slide in a large (400 ml) volume of 5 mM HEPES buffer containing 1 
mM EDTA (pH 7.4 at 20°C) for 10 s. Each slide was then placed in 100 ml of the same 
HEPES/EDTA buffer for a further 90 min at 20°C. At the end of this postincubation wash 
period slides were rapidly dipped in deionized water to remove buffer salts and the excess 
liquid aspirated from around each section. Slides were finally dried on a slide warmer 
(37°C) under a flow of room temperature air. 
The pharmacologic profile of [3H]dextrorphan binding sites was characterized in 
coronal sections taken from bregma -2.8 mm to -4.8 mm (Paxinos and Watson, 1986). 
For assessing the regional distribution of [3H]dextrorphan binding whole brains sectioned 
in horizontal, sagittal and coronal planes were studied. Representative sections were later 
stained with cresyl violet acetate to facilitate the identification of various brain regions in 
accordance with the atlas of Paxinos and Watson, 1986). With the exception of studies to 80 
determine the effects of 7-chlorokynurenic acid and D-AP5 on [3H]dextrorphan binding, 
which were done in the absence of added glutamate and glycine, standard conditions, as 
described above, were employed in all experiments. For equilibrium saturation studies, 
samples were taken from the incubation droplet prior to termination of the 4 h incubation 
period in order to accurately assess the final concentration of unbound radioligand. 
Autoradiography and data analysis 
Dried sections were placed in x-ray cassettes and apposed to Hyperfilm-3H 
(Amersham; Arlington Heights, IL); plastic tritium standards ([3H]Micro- scales; 
Amersham) were included with each film. After a 13 to 15 day exposure period at 20°C, 
films were developed in D-19 (Kodak; Rochester, New York) for 4 min, fixed in Kodak 
Rapid Fixer, rinsed and allowed to air dry. Autoradiograms were analyzed by computer-
assisted densitometry with a MCID image analysis system (Imaging Research Inc., St. 
Catherines, Ontario, Canada). [3H]Dextrorphan concentrations were determined from a 
standard curve constructed from the tissue equivalent concentrations of the images of the 
[3H]plastic standards (Geary and Wooten, 1983). Multiple sites (10-20 readings) were 
sampled in each brain area from quadruplicate sections (or single sections for time course 
studies). Specific [3H]dextrorphan binding was determined by subtracting mean binding in 
the presence of 100 µM MK-801 from mean total binding values for each particular brain 
area. 
For saturation analysis of [3H]dextrorphan binding, free radioligand concentrations 
(1 to 60 nM) were fit to nonspecific binding values for each brain area by linear least 
squares regression analysis.  Corresponding specific binding isotherms were fit to a 
hyperbolic equation using iterative nonlinear least squares regression analysis. The 81 
parameters of [H]clextrorphan association and dissociation kinetics were determined by 
fitting the following exponential equations: 
RB, =I[RB0J 
i=1 
RB, =I[RBeqj- (1 e-k4.1.5 
=1 
where, for site i of n total sites: RBt is the amount of radioligand bound at time t, RBo is 
the amount of radioligand bound at time t = 0, RBeq is the amount of radioligand bound at 
equilibrium, 1L1 is a dissociation rate constant, and kobs is an apparent association constant. 
Competition data were also analysed by computer-assisted nonlinear least squares 
regression analysis. Binding potencies (IC50) were determined by fitting the following 
logistic equation to the data: 
E= 
1+ (K I [X])" 
where E and E  are the response and maximal response, respectively, K is the IC50, X is 
the dose and n is a slope factor. Ki values were calculated from IC50 values based on the 
Cheng-Prusoff equation : Ki = IC50 / (1+ [L]/ICD) where [L] is the concentration of 
[3H]dextrorphan and KD is the dissociation constant for the particular brain region of 
interest. Regional differences in [3H]dextrorphan binding affinity and the effects of D-AP5 
and 7-chlorokynurenic acid on [3H]dextrorphan binding were statistically analysed by one-
way analysis of variance (ANOVA) followed by post hoc comparisons using the method of 
Bonferroni. 82 
Results
 
Characterization of [3H]dextrorphan binding to slide-mounted rat brain 
sections 
A study of preliminary autoradiographic images revealed a particularly high density 
of specific [3H]dextrorphan binding sites in the stratum radiatum of the CAl subfield of the 
hippocampal formation. As the stratum radiatum of CAl is not only a discrete and easily 
quantifiable brain area, but also appears to represent a region of high specific 
[3H]dextrorphan binding, this region of the hippocampus was specifically chosen for the 
initial characterization of [3H]dextrorphan binding parameters in slide-mounted rat brain 
sections. Preliminary images also showed that specific [3H]dextrorphan binding was 
greatly enhanced in all brain regions when assayed in low ionic strength buffer in tissue 
depleted of divalent cations. These findings with regard to both the choice of incubation 
buffer (5 mM HEPES, pH 7.4) and the high binding signal in the hippocampus are 
consistent with our earlier reports demonstrating [3H]dextrorphan binding in membranes 
prepared from rat brain homogenates (Franklin and Murray, 1990; Franklin and Murray, 
1992). 
In defining a procedure for autoradiographic visualization of [3H]dextrorphan 
binding sites initial kinetic studies were undertaken to determine the time course of 
[3H]dextrorphan association with its recognition sites in the stratum radiatum of CAl. In 
the absence of exogenously added glycine and glutamate specific [3H]dextrorphan binding 
required approximately 4 h to reach equilibrium at 20°C. Based on this information, 
sections were allowed to incubate with 40 nM [3H]dextrorphan for 4 h prior to immersion 
in a large volume (100 ml) of buffer in order to determine the optimum washout time to 
maximize the ratio of specific to nonspecific binding. The use of an excess volume to 
initiate dissociation of nonspecifically bound [3H]dextrorphan from sections (2000-fold 
dilution assuming 50 gl remains after the incubation droplet has been drained from the 
section) effectively eliminated rebinding of the radioligand. As shown in figure 5.1 (panel 83 
A), the fraction of nonspecific binding in the stratum radiatum of CAl was reduced in a 
time-dependent manner by rinsing sections at 20°C. This kind of profile has been 
described previously for [3H]MK -801 binding in sections of brain mash (Subramaniam 
and McGonigle, 1991). As highlighted in figure 5.1 (panel B), specific [3H]dextrorphan 
binding could not be detected following postincubation wash times of less than 10 min at 
20°C, but did manifest at wash times greater than 10 min. Maximum signal to noise ratios 
were obtained in the stratum radiatum of the CA1 subfield of the hippocampus by 
approximately 75 min and remained stable for up to 260 min. Reducing the temperature of 
the postincubation wash procedure to 4°C slowed the dissociation rate of nonspecifically 
bound [3H]dextrorphan considerably; maximum specific to nonspecific binding ratios were 
achieved at 180 min (data not shown). Attempts to expose slide-mounted sections, under 
our standard binding conditions, to wash temperatures of 37°C resulted in damage to the 
sections. Based on these data, a postincubation wash time of 90 min at 20°C was used for 
all subsequent studies. Independent determination of the dissociation rate of specific 
[3H]dextrorphan binding from the stratum radiatum of the CA1 subfield of the 
hippocampus by nonlinear regression analysis revealed a monophasic process with an 
estimated dissociation rate constant of 0.005 ± 0.001 min-1 at 20°C (data not shown). 
Using the optimized assay conditions the association kinetics of specific 
[3H]dextrorphan binding were studied in the presence and absence of exogenous glycine 
and glutamate (Figure 5.2). In the absence of exogenous glycine and glutamate at 20°C the 
association reaction of [3H]dextrorphan in the stratum radiatum of the CAl subfield of the 
hippocampus was found to be monophasic by nonlinear regression analysis with an 
apparent t 03 of 46 min.  Equilibrium, was obtained under these conditions at 
approximately 4 h and then remained stable until at least 8 h. The inclusion of 100 11M 
glycine and 1 1.1.M glutamate in the incubation droplet produced a marked increase in the 
apparent association rate of [3H]dextrorphan with its binding sites, decreasing the t  to to 
21 min. Maximal specific [3H]dextrorphan binding levels in the stratum radiatum of CA1 84 
were unchanged in the presence of exogenous glycine and glutamate; however they were 
routinely included in the binding assay in order to ensure that equilibrium was reached by 4 
h. 
To address the regional distributions of [3H]dextrorphan binding sites in brain, 
saturation analysis of [3H]dextrorphan binding was performed. Specific binding in the 
stratum radiatum of the CAl region of the hippocampus accounted for approximately 64-45 
% of total binding at [3H]dextrorphan concentrations ranging 5-60 nM. Nonlinear 
regression analysis of equilibrium saturation binding isotherms from a number of different 
brain regions indicated that in each region [3H]dextrorphan appears to label a single 
population of high affinity binding sites (Figure 5.3). Binding affinities ranged from 25.3 
± 8.8 nM in the inner frontoparietal cortex (layers IV-VI) to 48.7 ± 12.2 nM in the stratum 
radiatum of CA1 (Table 5.1). Significant variation among brain regions was found in the 
densities of [3H]dextrorphan binding sites, which ranged from 490 ± 68 fmol/mg tissue in 
the stratum radiatum of CAl to 113 ± 16 fmol/mg tissue in the lateral thalamic nuclei (Table 
5.1 and Figure 5.3). 
Regulation of [3H]dextrorphan binding by glycine and glutamate 
Our previous studies in membrane homogenates have shown that the regulation of 
[3H]dextrorphan binding by Mg2+ and the polyamine agonist spermidine is insensitive to 
the presence of glycine and glutamate (Franklin and Murray, 1992). Whereas the potencies 
of Mg2+ and spermidine as modulators of [311]TCP and [3H]MK -801 binding are 
significantly increased by the presence of exogenous glycine and glutamate in well washed 
membranes, their marked potencies as regulators of [3H]dextrorphan binding are 
unaffected by the presence or absence of these substances. 85 
FIGURE 5.1.
 
Determination of optimal postincubation wash time.
 
The effect of rinse time on [3H]dextrorphan binding was measured in the stratum radiatum 
of the CAl region of the rat hippocampus. Coronal sections (16-gm) were incubated with 
40 nM [3H]dextrorphan for 4 h at 20°C in the presence of glycine (100 gM) and glutamate 
(1 JIM). Following incubation sections were washed at 20°C in 5 mM HEPES buffer 
containing 1 mM EDTA for various time periods as indicated on the abscissa. (A) Time 
course of total [3H]dextrorphan binding (closed circles) and time course of nonspecific 
binding (open circles) defined in the presence of 100 ItM MK-801. Each point represents 
mean [3H]dextrorphan binding determined in single sections from a representative 
experiment.  (B) Specific [3H]dextrorphan binding profile (total minus nonspecific 
binding). 86 
FIGURE 5.1.
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FIGURE 5.2.
 
Time course of association of specific [3H]dextrorphan binding to stratum
 
radiatum of the CAI region of the rat hippocampus.
 
Coronal sections (two animals) were incubated with 40 nM [3H]dextrorphan either in the 
absence (open circle/dotted line) or presence (closed circles/solid line) of glycine (100 gM) 
and glutamate (1 liM). Incubation was allowed to proceed under humid conditions at 20°C 
for various time points as indicated on the abscissa. Sections were then washed for 90 min 
at 20°C in 5mM HEPES buffer containing 1 mM EDTA. Each point represents specific 
[3H]dextrorphan binding in single brain sections from a representative experiment. 
Nonspecific binding was defined by 10011M MK-801. 88 
FIGURE 5.2.
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FIGURE 5.3.
 
[3II]Dextrorphan equilibrium saturation binding isotherms from rat brain at
 
the level of: (A) stratum radiatum of the CA1 region of the hippocampus,
 
(B) dentate gyrus (molecular layer), (C) outer frontoparietal cortex (layers 
II-III) and (D) lateral thalamus. 
Coronal sections were incubated with increasing concentrations of [3H]dextrorphan for 4 h 
at 20°C in the presence of added glycine (100 11M) and glutamate (111M). Incubation 
droplets were sampled at 4 h to determine the free radioligand concentration as indicated on 
the abscissa. Sections were washed for 90 min at 20°C in 5 mM HEPES buffer containing 
1 mM EDTA. Each point represents the mean [3H]dextrorphan binding determined in 
quadruplicate brain sections from a representative experiment repeated twice with similar 
results. Nonspecific binding was defined by 100 RM MK-801. 90 
FIGURE 5.3.
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TABLE 5.1. 
Equilibrium saturation binding of [3H]dextrorphan in various brain 
regions 
Brain region  KD ± S.E.  Bmax ± S.E. a 
nM  fmol/mg 
Hippocampus (CA1 radiatum)  48.7 ± 12.2  490 ± 68 
Dentate gyrus (molecular layer)  40.5 ± 13.5  332 ± 58 
Outer cortex (layers 11-111)  36.2 ± 16.1  189 ± 42 
Inner cortex (layers IV-VI)  25.3 ± 8.8  134 ± 20 
Lateral thalamus b  30.3 ± 9.4  113 ± 16 
[3H]Dextrorphan binding and autoradiographic procedures were followed as described 
in Materials and Methods. ICD and B. values are derived from nonlinear regression 
analysis-based fitting of a hyperbolic equation to the data. 
a Regional density values are expressed as [3H]dextrorphan bound in fmol/mg tissue 
(wet weight) by calibrating the images produced by the tritium-embedded plastic 
standards for each film to their known tissue equivalent concentrations. 
b Includes ventroposteromedial, ventral posterolateral and ventrolateral thalamic nuclei. 
The inability of exogenously added glycine and glutamate, at equilibrium, to 
significantly enhance maximal specific binding of noncompetitive NMDA antagonists in 
slide-mounted brain sections has been attributed to the  presence of high levels of 
endogenous glycine and glutamate remaining in the sections. It is possible, therefore, that 
the effects of exogenous glycine and glutamate on [3H]dextrorphan binding  are blunted 
under our standard assay conditions. In practice, it is not feasible to deplete slide-mounted 
of endogenous glycine and glutamate as washing procedures have to be curbed in the 
interests of preserving the anatomical integrity of the tissue. 92 
To address this issue we compared the effects of glycine and glutamate in sections 
that, prior to the radioligand incubation, had been pre-washed for 1 h at 20°C or extensively 
washed for an additional 16 h at 4°C. The magnitude of specific [3H]dextrorphan binding 
at equilibrium appears, however, to be relatively insensitive to added glycine and glutamate 
even after prolonged pre-washing of the sections (Figure 5.4). Under standard pre-wash 
conditions some concentrations of glutamate modestly enhanced specific [3H]dextrorphan 
binding in the stratum radiatum of CA1 by 20 to 35 %, but these increases were not 
significant.  Following extensive pre-washing of sections, the addition of glutamate 
consistently produced very modest increments in [3H]dextrorphan binding which were not 
statistically significant (Figure 5.4A). Exogenous glycine produced no significant change 
in specific [3H]dextrorphan binding levels in the stratum radiatum of CA1 following 
standard or prolonged pre-washing of brain sections (Figure 5.4B). Other brain regions 
were equally insensitive to the addition of glycine and glutamate despite attempts to remove 
endogenous factors by extensive pre-washing of the sections. Specific [3H]dextrorphan 
binding, measured under equilibrium conditions, in the molecular layer of the dentate 
gyrus, outer (II-III) and inner (IV-VI) layers of the frontoparietal cortex and the lateral 
thalamic nuclei was not significantly changed by the addition of glycine or glutamate (data 
not shown). 
The modest stimulation of [3H]dextrorphan binding by glycine and glutamate 
following extensive washing protocols suggests that specific [3H]dextrorphan binding is 
unusually insensitive to glycine and glutamate. This is in marked contrast to the binding 
properties of [3H]MK -801 characterized under equilibrium conditions by Sakurai et al. 
(1991) in extensively washed sections. In that .study, 100 tiM NMDA was reported to 
enhance [3H]MK -801 binding in the stratum radiatum of the CA1 subfield of the 
hippocampus and molecular layer of the dentate gyrus by 181 % and 214 % respectively, 
whilst 10011M glycine alone was reported to increase [3I-INK-801 binding 255 % in the 
molecular layer of the dentate gyrus. 93 
FIGURE 5.4. 
Effect of (A) glutamate and (B) glycine on specific [3H]dextrorphan 
binding to  stratum radiatum of the CA1 region of the hippocampus 
following standard (1 h) or prolonged (16 h) pre-washing of slide-mounted 
sections. 
Coronal rat brain sections were washed in 5 mM HEPES (pH 7.4) either for 3 x 20 min at 
20°C or for an extra 16 h at 4°C prior to the standard pre-washing procedure before being 
allowed to air dry. Pre-washed sections were incubated with 40 nM [3H]dextrorphan for 4 
h either in the absence (white bars) or in the presence (hatched bars) of increasing 
concentrations (0.1-300 tiM) of glutamate or glycine. Bars represent mean specific 
[3H]dextrorphan binding ± S.E. determined in quadruplicate sections from a representative 
experiment. Nonspecific binding was defined by 100 RM MK-801. 94 
FIGURE 5.4.
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In contrast to the lack of effect of exogenous glycine and glutamate, 
[3H]dextrorphan binding was potently inhibited in a concentration-dependent manner both 
by the strychnine-insensitive glycine site antagonist 7-chlorokynurenic acid (Figure 5.5) 
and the competitive NMDA antagonist D-AP5 (Figure 5.6) when measured in the absence 
of added glycine and glutamate. These data suggest that the NMDA receptor agonist and 
co-agonist sites are saturated by endogenous glutamate and glycine respectively and that 
activation of these sites is an absolute requirement for specific [3H]dextrorphan binding to 
occur. This occupancy of the agonist and co-agonist sites by endogenous glutamate and 
glycine is surmountable in the presence of increasing concentrations of 7-chlorokynurenic 
acid and D-AP5 
The inhibition of [3H]dextrorphan binding by 7-chlorokynurenic acid was studied 
in detail in four different brain areas (Figure 5.5). The inhibitory potencies of 7­
chlorokynurenic acid to suppress [3H]dextrorphan binding in the stratum radiatum of the 
CAl region of the hippocampus, lateral thalamus or outer (11-111) and inner (IV-VI) layers 
of the frontoparietal cortex were similar (Table 5.2). The potency of 7-chlorokynurenic 
acid to inhibit [3H]dextrorphan binding in the inner cortex (Ki = 2.8 ± 0.7 11M) was, 
however, significantly different from that of the stratum radiatum of hippocampal area CAl 
(6.8 ± 0.6 gM) (P < 0.05, Bonferroni procedure). D-AP5, moreover, exhibited a 
moremarked regional variation (P < 0.0001, ANOVA) in its ability to inhibit 
[3H]dextrorphan binding when studied in the same four brain areas (Figure 5.6 and Table 
5.2). Specific [3H]dextrorphan binding was most potently inhibited by D-AP5 in the 
cortical layers, with Ki values of 0.89 ± 0.811M (layers 11-III) and 0.85 ± 0.6 µM (layers 
IV-VI). D-AP5 inhibition of [3H]dextrorphan binding was significantly less potent than 
cortex (P < 0.001, Bonferroni procedure) in the stratum radiatum of CAl (11.2 ± 0.8 iiM) 
and approximately 20-fold less potent (P < 0.001, Bonferroni procedure) than the cortex in 
the lateral thalamic nuclei (20.0 ± 0.811M). 96 
FIGURE 5.5.
 
Regional inhibition of specific [3H]dextrorphan binding by
 
7-chlorokynurenic acid in rat brain.
 
Coronal sections were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the 
presence of increasing concentrations of 7-chlorokynurenic acid (7-C1-KYNA) as indicated 
on the abscissa. Sections were then washed for 90 min at 20°C in 5 mM HEPES buffer 
containing 1 mM EDTA. The symbols describe the actual data points for each brain region 
and the curves are expanded from the parameter estimates derived from fitting a logistic 
equation to the data by means of iterative nonlinear least squares regression analysis. Each 
point represents mean specific [3H]dextrorphan binding ± S.E. determined in quadruplicate 
sections from a representative experiment. Nonspecific binding was defined by 100 11M 
MK-801. 
FIGURE 5.6.
 
Regional inhibition of specific [3H]dextrorphan binding by D-AP5
 
in rat brain.
 
Coronal sections were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the 
presence of increasing concentrations of D-AP5 as indicated on the abscissa. Sections were 
then washed for 90 min at 20°C in 5 mM HEPES buffer containing 1 mM EDTA. The 
symbols describe the actual data points for each brain region and the curves are expanded 
from the parameter estimates derived from fitting a logistic equation to the data by means of 
iterative nonlinear least squares regression analysis. Each point represents mean specific 
[3H]dextrorphan binding ± S.E. determined in quadruplicate sections from a representative 
experiment. Nonspecific binding was defined by 10011M MK-801. 97 
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TABLE 5.2. 
Potencies of 7-chlorokynurenic acid and D-AP5 to inhibit 
[3H]dextrorphan binding in various brain regions 
7-C1-KA  D-AP5 
Brain region  Ki ± S.E.  Ki ± S.E. 
PM  PM 
Hippocampus (CA1 radiatum)  6.8 ± 0.6 a  11.2 ± 0.8 b 
Outer cortex (layers 11 -B1)  5.2 ± 0.8  0.89 ± 0.8 
Inner cortex (layers IV-VI)  2.8 ± 0.7  0.85 ± 0.6 
Lateral thalamus d  3.8 ± 0.5  20.0 ± 0.8 C 
[3H]Dextrorphan binding and autoradiographic procedures were followed as described 
in Materials and Methods. Data were fit to a one-site logistic equation by iterative 
nonlinear least squares regression analysis. Differences between ICi values were 
significantly different for 7-chlorokynurenic acid at P < 0.001 and D-AP5 at P < 
0.0001 by ANOVA and post tests using the method of Bonferonni as indicated. 
Significantly different than inner cortex (P < 0.05). 
b Significantly different than cortical areas (P < 0.001). 
Significantly different than stratum radiatum of CAl (P < 0.01) and cortical areas 
(P < 0.001). 
'Includes ventroposteromedial, ventral posterolateral and ventrolateral thalamic 
nuclei. 
Pharmacologic profile of [3H]dextrorphan binding 
In order to establish the pharmacologic specificity of [3H]dextrorphan binding, we 
evaluated concentration-response relationships of a number of noncompetitive NMDA 
antagonists as competitors for specific [3H]dextrorphan equilibrium binding. Competition 
curves are shown for two brain areas that exhibit high densities of [3H]dextrorphan binding 
sites, the stratum radiatum of hippocampal area CAl (Figure 5.7) and the outer layers of 
the frontoparietal cortex (Figure 5.8).  In contrast to our findings in membrane 100 
homogenates (Franklin and Murray, 1992), all compounds displaced [3H]dextrorphan in a 
monophasic manner suggesting interaction with a single high- affinity binding site in both 
brain areas. Although quantitative receptor autoradiography permits the pharmacologic 
characterization of discrete brain regions, long postincubation wash periods such as we 
employed here may not permit detection of a low affinity [3H]dextrorphan binding sites in 
slide-mounted tissue. 
With the exception of unlabelled dextrorphan, all compounds were either similar 
(MK-801, TCP) or less potent (PCP, dextromethorphan) inhibitors of [311]dextrorphan 
binding in the outer cortex than in the stratum radiatum of CAl (Table 5.3). MK-801 was 
the most potent inhibitor of [3H]dextrorphan binding both in the stratum radiatum of 
hippocampal area CAl and the outer cortex, with Ki values of 2.5 ± 0.6 nM and 2.7 ± 0.6 
nM respectively. The rank order of potency for displacement of [3H]dextrorphan binding 
in the stratum radiatum of CAl was as follows: MK-801 > TCP > PCP > dextrorphan > 
ketamine > dextromethorphan (Table 5.3). A similar pattern was observed in the outer 
cortex: MK-801 > TCP > dextrorphan > PCP > ketamine > dextromethorphan, but with 
dextrorphan being approximately 2-fold more potent than PCP, xi values were 33.5 ± 0.7 
nM and 60.1 ± 0.6 nM respectively (Table 5.3).  Of the compounds tested 
dextromethorphan was the least potent inhibitor of [3H]dextrorphan binding; 
dextromethorphan was over 6-fold less potent than dextrorphan in the stratum radiatum of 
CAl. The potent inhibitory effects of dextrorphan in the outer cortex, however, render 
dextromethorphan approximately 30-fold less potent than dextrorphan in this brain area. 101 
FIGURE 5.7.
 
[3H]Dextrorphan competition binding in stratum radiatum of the CAI
 
region of rat hippocampus.
 
Sections were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the presence of 
added glycine (100 gM) and glutamate (1 p.M). Sections were then washed for 90 min in 5
mM HEPES buffer containing 1 mM EDTA.  Binding of MK-801, TCP, PCP,
dextrorphan (DX), ketamine and dextromethorphan (DXM) is depicted by plots of the 
actual data points. The respective curves are expanded from the parameter estimates 
derived from fitting a logistic equation to the data by means of iterative nonlinear least 
squares regression analysis. Each point represents mean specific [3H]dextrorphan binding 
determined in quadruplicate sections from a representative experiment. The S.E. for each 
point was less than 10 % of the mean. Nonspecific binding was defined by 100 pM MK­
801. 
FIGURE 5.8.
 
[3H]Dextrorphan competition binding in outer frontoparietal cortical layers
 
of rat brain. 
Sections were incubated with 40 nM [311]dextrorphan for 4 h at 20°C in the presence of 
added glycine (100 pM) and glutamate (1 gM). Sections were then washed for 90 min in 5 
mM HEPES buffer containing 1 mM EDTA. Binding of MK-801, TCP, dextrorphan 
(DX), PCP, ketamine and dextromethorphan (DXM) is depicted by plots of the actual data 
points. The respective curves are expanded from the parameter estimates derived from 
fitting a logistic equation to the data by means of iterative nonlinear least squares regression 
analysis. Each point represents mean specific [3H]dextrorphan binding determined in 
quadruplicate sections from a representative experiment. The S.E. for each point was less 
than 10 % of the mean. Nonspecific binding was defined by 100 pM MK-801. 102 
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TABLE 5.3.
 
Potencies of competitors for [3H]dextrorphan binding to stratum
 
radiatum of the CA1 region of the hippocampus and outer cortical
 
layers (11-III)
 
CAl  Outer cortex 
Compound  Ki ± S.E  Ki ± S.E. 
nM  nM 
MK-801  2.5 ± 0.6  2.7 ± 0.6 
TCP  9.4 ± 0.6  12.2 ± 0.7 
PCP  43.3 ± 0.7  60.1 ±0.6 
Dextrorphan  116.6 ± 0.6  33.5 ± 0.7 
Ketamine  231.7 ± 0.7  360.0 ± 0.9 
Dextromethorphan  760 ± 0.6  1037  ± 0.3 
[311]Dextrorphan binding and autoradiographic procedures were followed as described 
in Materials and Methods. Data were fit to a one-site logistic equation by iterative 
nonlinear least squares regression analysis. 
Regional distribution of [3H]dextrorphan binding sites 
To further assess the regional distribution of [3H]dextrorphan binding sites the 
specific binding of a fixed concentration of the radioligand was determined in 23 brain 
structures. The representative autoradiograms shown in figure 5.9 were generated from 
adjacent coronal brain sections; total [3H]dextrorphan binding is shown in panel A and 
nonspecific binding measured in the presence of 100 1.LM MK-801 in panel B. These 
colour-coded images clearly show high densities of [3H]dextrorphan binding sites localbrd 
in distinct regions of the hippocampal formation and the superficial layers of the cortex. In 105 
addition, moderate levels of [3H]dextrorphan binding are found in the deeper layers of the 
cerebral cortex and the thalamic nuclei. 
A summary of the neuroanatomical distribution of [3H]dextrorphan binding sites is 
presented in Table 5.4. These data are in agreement with the differences observed in 
relative densities of [3H]dextrorphan binding sites determined by equilibrium saturation 
analysis: stratum radiatum (CA1) > dentate gyms > outer cortex >inner cortex > thalamus 
(Table 5.1). The highest density of specific [3H]dextrorphan binding was seen in the 
stratum radiatum of the CAl region of the hippocampus (181.5 ± 14.6 fmol/mg). Binding 
densities were also high in the stratum oriens of CAl and the molecular layer of the dentate 
gyrus, and somewhat lower in the stratum lacunosum moleculare of CA!, stratum radiatum 
of CA3 and stratum oriens of CA3 as shown in detail in figure 5.10 (A-C). In contrast, the 
stratum pyramidale and the granule cell layer of the dentate gyms, which correspond to the 
dense cell body layers of these areas, showed lower levels of [3H]dextrorphan binding 
(Figure 5.10 A-C). 
Two other areas of relatively high specific [3H]dextrorphan binding were the outer 
layers of the cortex (1-111) and the molecular layer of the cerebellum (Table 5.4). In both 
these brain regions the density of binding sites was approximately 50 % of that measured in 
the stratum radiatum of the CAl region of the hippocampus. Deeper layers (IV-VI) of the 
cortex showed less [3H]dextrorphan binding than the outer layers (II-M. Whilst the 
highlevels of [3H]dextrorphan binding observed in the superficial layers of the cortex, 
together with the pronounced distribution of sites in the hippocampal formation, are largely 
consistent with other autoradiographic studies that have employed a variety of radioligands 
to label the NMDA receptor, our fmdings with regard to the cerebellum represent a pattern 
unique to [3H]dextrorphan binding. 106 
FIGURE 5.9.
 
Representative autoradiograms depicting (A) total [3H]dextrorphan binding
 
and (B) nonspecific binding measured in the presence of 100 RM MK-801.
 
Adjacent coronal rat brain sections (16-pm) were incubated with 40 nM [3H]dextrorphan 
for 4 h at 20°C in the presence of glycine (100 IIM) and glutamate (1 pM). Sections were 
then washed for 90 min at 20°C in 5 mM HEPES buffer containing 1 mM EDTA, dried and 
apposed to tritium-sensitive film for 13 days with a complete set of tritium-standards of 
known radioactivity. Colour has been assigned to the scale representing binding site 
density so that the highest levels of [3H]dextrorphan binding appear red to orange and the 
lowest levels appear blue to pink. The dense sporadic labelling around the outer edges of 
the sections is also seen in areas where the tissue section has been damaged or in and 
around the ventricles and is an artifact of interaction of [3H]dextrorphan with the 
embedding medium. This phenomenon is not unique to [3H]dextrorphan and has been 
described previously for other ligands such as [3H]TCP (McDonald et al., 1989). 107 
FIGURE 5.9. 108 
TABLE 5.4.
 
Regional distribution of [3H]dextrorphan ([3H]DX) binding sites in the
 
rat brain
 
PHMextrorphan bound (fmol/mg) a 
Brain region (abbreviation)  Relative to CAI 
Mean ± S.E.  stratum radiatum (%) 
Cortex 
Frontal layers II-D1 (Fr II -III)  89.8 ± 73  493 
Frontal layers IV-VI (Fr IV-VI)  623 ± 7.8  34A 
Frontoparietal layers 11-111 (FrPa 11-M)  893 ± 4.2  49.3
 
Frontoparietal layers IV-VI (FrPa IV-VI)  61.0 ± 3.8  33.6
 
Entorbinal layers II-III (Ent 11-M)  82.0 ± 4.9  45.2
 
Entorhinal layers IV-VI (Ent. IV-VI)  492 ± 5.0  27.1
 
Illppocampal formation 
CA1-stratum lacunosum moleculare (LMol)  1193 ± 7.4  65.7 
CAI-stratum radiatum (Rad)  181.5 ± 14.6  100.0 
CAI-stratum pyramidale (Py)  79.8 ± 62  44.0 
CA1-stratum omens (Or)  167.6 ± 17.0  923 
CA3-stratum radiatum  119.3 ± 10.6  65.7 
CA3-stratum pyramidale  46.2 ± 4.9  253 
CA3-stratum origins  121.8 ± 11.1  67.1 
Dentate gyrus-stratum moleculare (DO-Mol)  159.1 ± 10.7  87.7 
Thalamic nuclei 
laterodorsal (LD)  65.5 ± 4.8  36.1 
mediodorsal (M1))  50.0 ± 7.6  27.6 
medial genicalate (MG)  39.6 ± 4.2  21.8 
ventroposterior (VP)  63.2 ± 4.3  34.8 
Cerebellum b 
Molecular layer (Cb-Mol)  87.0 ± 11.4  47.9 
Granule layer (Cb-Gr)  27.3 ± 83  15.0 
Caudate putamen (CPu)  52.8 ± 2.9  29.1 
Central gray (CG)  10.8 ± 3.0  6.0 
Corpus callosum (cc)  03 ± 02  0.2 
a Values represent mean specific binding ± S.E. of measurements made from 
autoradiograms generated from quadruplicate sections at each brain level from three 
animals. 
b Specific [3H]DX binding was calculated using representative values from 
hippocampus (CA1), as nonspecific [3H]DX binding in the cerebellum is inadequately 
defined by 100 p.M MK-801. 109 
FIGURE 5.10.
 
Detail of the rat hippocampal formation in the sagittal plane.
 
(A) Autoradiogram showing the distinct laminar distribution of [3H]dextrorphan binding 
sites under the same conditions as Fig. 9. PHIDextrorphan binding is particularly dense in 
the stratum oriens and stratum radiatum of CA1 and the molecular layer of the dentate 
gyrus. 
(B) Section stained with cresyl violet acetate for comparison with the autoradiogram. Dark 
bands correspond to the pyramidal cell layer of the hippocampus and granule cell layer of 
the dentate gyrus. 
(C) Line drawing corresponds to Lateral 2.40 mm in accordance with the atlas of Paxinos 
and Watson (1986). Abbreviations are as follows: CA1-3, fields CA1-3 of Ammon's 
horn; Or, oriens layer, Py, pyramidal cell layer; Rad, stratum radiatum; LMol, lacunosum 
moleculare of hippocampus; DG, dentate gyms; Gr, granule layer of dentate gyrus; Mol,
molecular layer of dentate gyrus. 110 
FIGURE 5.10.
 
C 
6k-l- N\ 
L
X 
'CA2  ..., - \t-I10/ r­ %-/A..... ...--­ . 
Lateral 2.40mm
 111 
Autoradiographic visualization of specific [3H]dextrorphan binding sites in the 
cerebellum revealed a distinct pattern of distribution.  [311]Dextrorphan binding was 
particularly concentrated in the cerebellar molecular layer where there was over a three-fold 
greater density of labelled sites than in the granule cell layer (Table 5.4). The location of 
the outer molecular layer and the innermost granule cell layer of the cerebellar cortex is 
shown in figure 5.11. The representative autoradiograms shown in figures 5.12 and 5.13 
were generated from two sets of adjacent sagittal sections of cerebellum.  Total 
[3H]dextrorphan binding is shown in figure 5.12 panel A and nonspecific binding 
measured in the presence of 100 pM unlabelled dextrorphan in figure 5.12 panel B. 
[3H]Dextrorphan binding is concentrated in the molecular cell layer and becomes more 
diffuse in the granule cell layer of all folia. Total [3H]dextrorphan binding is also shown in 
figure 5.13 panel A and, from the corresponding adjacent section, figure 5.13 panel B 
shows [3H]dextrorphan binding in the presence of 100 1.1M MK-801. As highlighted in 
figure 5.13, images produced in the presence of unlabelled MK-801 (panel B) are largely 
indistinguishable from total [3H]dextrorphan binding (panel A of figures 5.12 and 5.13 ). 
Competition analysis revealed that unlabelled dextrorphan displaces 
[3H]dextrorphan from the molecular cell layer and granule cell layer in  a monophasic 
manner suggesting interaction with a single binding site (Figure 5.14); IC50 values = 2.7 ± 
0.7 LiM and 5.9 ± 0.9 pM for the molecular and granule cell layers respectively. In self-
competition studies, dextrorphan was approximately 20-fold less potent in the molecular 
layer and 50-fold less potent in the granule cell layer of the cerebellum than in the stratum 
radiatum of the CA1 region of the hippocampus. These differences  are even more 
pronounced when comparing the potency of unlabelled dextrorphan to displace 
[3H]dextrorphan from the cerebellum and the outer cortical layers (Table 5.3).  MK-801, 
however, does not compete for sites labelled by [3H]dextrorphan in either the molecular 
cell layer or the granule cell layer of the cerebellum (Figure 5.14) . 112 
Our previous studies in membrane homogenates (Franklin and Murray, 1992) 
indicated that [3H]dextrorphan labels a population of binding sites in the cerebellum that 
display lower affinity for MK-801 and TCP than do forebrain [3H]dextrorphan sites. 
Based on our earlier characterization of [3H]dextrorphan binding in cerebellar membranes, 
together with the fact that [3H]MK -801 has such low affinity for the NMDA receptors in 
the cerebellum that specific binding is often undetectable by receptor autoradiography in 
this brain region (Bowery et al. 1988; Monaghan, 1991; Sakurai et al., 1991), it would 
appear that the [3H]dextrorphan binding site in cerebellum is distinct from forebrain NMDA 
receptors which recognize [3H]MK -801 with high affinity in this brain area. 
Moderate levels of [3H]dextrorphan binding were seen in the thalamus (Table 5.4), 
with highest densities in the dorsolateral and ventral posterior thalamic nuclei. The caudate­
putamen also showed moderate levels of specific [3H]dextrorphan binding, approximately 
30% of that measured in the stratum radiatum of the CAl region of the hippocampus. Of 
the areas studied, the lowest levels of [3H]dextrorphan binding were seen in the granule 
cell layer of the cerebellum and the central grey. White matter tracts such as the corpus 
callosum and the white matter of the cerebellum showed practically no specific 
[3H]dextrorphan binding. White matter does demonstrate greater self-absorption of beta-
particles emitted by tritium than gray matter (Alexander et al., 1981). Consequently, 
quenching of tritium-labelled ligands has been shown to change in relation to the white 
matter content of a particular brain region (Rainbow et al., 1984). The low level of 
[3H]dextrorphan binding observed in white matter tracts is, however, consistent with other 
descriptions of NMDA receptor distribution. 
We have compared the regional distribution of [3H]dextrorphan binding sites 
obtained in the present study with previously reported distributions of NMDA receptors 
determined by ligand autoradiography. To facilitate these comparisons, density values 
were expressed as the percentage of binding relative to the stratum radiatum of the CAl 
region of the hippocampus reported for each radioligand. Support for a relationship 113 
FIGURE 5.11.
 
Stained sagittal section of rat cerebellum.
 
Sagittal section of rat cerebellum stained with cresyl violet 
acetate for comparison with autoradiograms depicted in 
figures 5.12. and 5.13.  Dark bands correspond to the 
granule (Gr) cell layer characterized by densely packed cell 
bodies. The outer molecular (Mol) cell layer consists largely 
of Purkinje cell dendrites. 114 
FIGURE 5.12.
 
Representative autoradiograms derived from sagittal  sections of rat
 
cerebellum depicting (A) total [3H]dextrorphan binding and (B) nonspecific
 
binding measured in the presence of 100 gM unlabelled dextrorphan.
 
Autoradiograms derived from rat cerebellum depicting: (A) total [3H]dextrorphan binding 
and (B) nonspecific binding measured in the presence of 100 11M dextrorphan. Sagittal 
sections (16-gm) were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the 
presence of glycine (100 gM) and glutamate (111M). Sections were then washed for 90 
min at 20°C in 5 mM HEPES buffer containing 1 mM EDTA, dried and apposed to tritium-
sensitive film for 13 days with a complete set of tritium- standards of known radioactivity. 
Colour has been assigned to the scale representing binding site density so that the highest 
levels of [3H]dextrorphan binding appear red to orange and the lowest levels appear blue to 
pink. 
FIGURE 5.13.
 
Representative autoradiograms derived from sagittal  sections of rat
 
cerebellum depicting (A)  total  [3H]dextrorphan  binding  and  (B)
 
[3H]dextrorphan binding measured in the presence of 100 I.LM MK-801.
 
Autoradiograms derived from rat cerebellum depicting: (A) total [3H]dextrorphan binding 
and (B) [3H]dextrorphan binding measured in the presence of 100 pM MK-801. Sagittal 
sections (16-grn) were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the 
presence of glycine (100 liM) and glutamate (1 gM). Sections were then washed for 90 
min at 20°C in 5 mM HEPES buffer containing 1 mM EDTA, dried and apposed to tritium-
sensitive film for 13 days with a complete set of tritium-standards of known radioactivity. 
Colour has been assigned to the scale representing binding site density so that the highest 
levels of [3H]dextrorphan binding appear red to orange and the lowest levels appear blue to 
pink. 115 
FIGURE 5.12.
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FIGURE 5.14. 
[311]Dextrorphan competition binding in the molecular and granule cell 
layers of the rat cerebellum. 
Competition binding in the molecular (Mol) and granule (Gr) cell layers of the rat 
cerebellum. Sections were incubated with 40 nM [3H]dextrorphan for 4 h at 20°C in the 
presence of added glycine (10011M) and glutamate (1 I.LM). Sections were then washed for 
90 min in 5 mM HEPES buffer containing 1 mM EDTA. Binding of dextrorphan (DX) 
and MK-801 is depicted by plots of the actual data points. The respective curves are 
expanded from the parameter estimates derived from fitting a logistic equation to the data by 
means of iterative nonlinear least squares regression analysis. Each point represents mean 
specific [3H]dextrorphan binding determined in quadruplicate sections from a representative 
experiment. The S.E. for each point was less than 10 % of the mean. Nonspecific binding 
was defined by 10011M dextrorphan. 118 
FIGURE 5.14.
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between the regional distribution of NMDA receptors and [3H]dextrorphan binding sites is 
provided by the strong correlation (r=0.78, P < 0.002) between the occurrence of 
[3H]dextrorphan binding sites and the regional distribution of NMDA-displaceable 
[3H]glutamate binding sites described by Monaghan and Cotman (1985) (Figure 5.15A). 
Furthermore, there is an excellent correlation between the distribution of [3H]dextrorphan 
binding sites and those sites labelled by other noncompetitive NMDA antagonists. The 
regional distribution of [3H]dextrorphan labelled NMDA receptors was significantly 
correlated (r.90, P < 0.0001) with [3H]TCP binding sites described by Gundlach et al. 
(1986) (Figure 5.15B) and also with [31-I]MK-801 binding sites (r.90, P < 0.0001) 
described by Sakurai et al. (1991) (Figure 5.15C). 
The distinct laminar pattern of [3H]dextrorphan binding within the hippocampal 
formation was in marked concordance with the distribution of [3H]MK -801, [3H]TCP and 
NMDA-displaceable [3H]glutamate binding sites in the hippocampus. Despite the apparent 
similarities in the regional distribution of [3H]dextrorphan binding sites and those sites 
labelled by [3H]MK -801, [3H]TCP and NMDA-sensitive [311]glutamate, some differences 
were observed particularly in the relative percentages of binding in various brain regions. 
NMDA-displaceable [3H]glutamate, [3H]TCP and to a lesser extent [3H]MK -801, label a 
comparatively greater fraction of binding sites in the superficial layers of the cerebral cortex 
than [3H]dextrorphan which shows approximately 50 % of the binding levels seen in the 
stratum radiatum of CAL The most smiting disparity, however, between [3H]dextrorphan 
binding sites and those sites labelled by NMDA-displaceable [3H]glutamate, [3H]TCP or 
[3H]MK -801, is in the molecular layer of the cerebellum (Figure 5.15, point 27). In fact, 
if data from the cerebellum are omitted, linear-regression analysis reveals an improvement 
in the correlation between [3H]dextrorphan binding site distribution and those sites labelled 
by NMDA-displaceable [31I]glutamate (r=0.87, P < 0.001), [3H]MK -801 (r=0.95, P < 
0.0001) or [3H]TCP (r=0.97, P < 0.0001) (data not shown). 120 
FIGURE 5.15. 
Correlation between the regional distribution of [3H]dextrorphan binding 
sites  in  rat brain and  those  sites  labelled  by NMDA-sensitive 
[3H]glutamate, [3H]TCP, [3H]MK -801 and [3H]dextromethorphan. 
Correlation between the regional distribution of [3H]dextrorphan binding sites in rat brain 
and (A) NMDA-sensitive [3H]glutamate sites in rat brain (r).78, P < 0.002) from the data 
of Monaghan and Cotman (1985); (B) sites labelled by [3H]TCP in rat brain (r-4.90, P < 
0.0001) from the data of Gundlach et al. (1986); (C) sites labelled by [311]MK-801 in rat 
brain (r-4).90, P < 0.0001) from the data of Sakurai et al. (1991) and (D) sites labelled by
[311]dextromethorphan in guinea pig brain (r=-0.26, P < 0.5) from the data of Canonet al. 
(1989). The significance of the correlations was evaluated by t test of the probability of
r=0 for each of the comparisons. All radioligand binding values are expressed as the
percentage of binding relative to the stratum radiatum of the CA1 region of the 
hippocampus. Abbreviations are taken from Table 4: (1) CA1-Rad, (2) DG-Mol, (3) CA1­
Or, (4) CA 1-LMol, (5) CA1 -Py, (6) CA3-Rad, (7) CA3 -Or, (8) CA3-Py, (9) Rad, (10)
Or, (11) LMo1, (12) Py, (13) CPu, (14) Fr II-III, (15) Fr IV-VI, (16) Fr Pa II-III, (17) 
Fr Pa IV-VI, (18) Ent II-III, (19) Ent IV-VI, (20) LD, (21) MD, (22) MG, (23) VP, (24) 
cc, (25) CG, (26) Cb-Gr, (27) Cb-Mol. 121 
FIGURE 5.15.
 
0  50  100
 
[ H]DX binding density

(% of CA1 radiatum)
 
1
 100 - r=0.90  9
 
2
 
1
 10
 
16
  11
 
23  17
 
20
 13
 
25  28 12
 
27  B 0 24
  , 
1 .
I 
0  50  100
 
[ H]DX binding density

(% of CA1 radiatum)
 
0 A  I
 
O  50  100
 
[ H]DX binding density

(% of CA1 radiatum)
 
8
 
25  r=-0.26 
23 13
 
14 011 
28 5  1
 
27
 
18
 
24
 
D 
0 
1
 
O  50  100
 
[ H]DX binding density

(% of  CA1 radiatum)
 122 
In contrast, there was no significant correlation (r=-0.26, P < 0.5) with the regional 
distribution of [3H]dextrorphan binding sites described herein and those labelled with 
[3H]dextromethorphan in guinea pig brain reported by Canoll et al. (1989) (Figure 5.15D). 
[3H]Dextromethorphan recognition sites in rat brain (Torte lla et al., 1989) follow a similar 
pattern of distribution to binding sites labelled in guinea pig brain and also appear to be 
unrelated to [3-I]dextrorphan-labelled NMDA receptors (data not shown). 
Discussion 
We have characterized [3H]dextrorphan binding sites in slide-mounted rat brain 
sections and ascertained their regional distribution using quantitative receptor 
autoradiography.  The present studies extend our previous findings in membrane 
homogenates (Franklin and Murray, 1990; Franklin and Murray, 1992) in that 
[3H]dextrorphan appears to selectively label a high affinity site localized within an open 
channel domain of the NMDA receptor. The [3H]dextrorphan binding site may not, 
however, be identical to ion channel binding sites labelled by other noncompetitive 
antagonists. Specifically, differences in the regulation of [3H]dextrorphan binding by 
glycine and glutamate and the labelling of high affinity sites in the cerebellum distinguish 
[3H]dextrorphan binding from that of either [3H]MK -801 or [3H]TCP. 
In agreement with our observations in membrane homogenates (Franklin and 
Murray, 1992), the association kinetics of [3H]dextrorphan with its binding site are slow in 
slide-mounted brain sections following standard washing conditions designed to deplete 
endogenous glycine and glutamate from the sections. In the absence of supplementary 
glycine and glutamate, an incubation period of at least 4 hours at room temperature is 
required to reach. The addition of exogenous glycine and glutamate to the incubation 
droplet, however, increases the apparent association rate of [3H]dextrorphan without any 
demonstrable change in the number of binding sites in CA1 ; equilibrium is reached in 123 
150 min. An acceleration in the association rate of [31Ildextrorphan is presumably a result 
of the ability of glycine and glutamate to facilitate access of [3Hjdextrorphan to a binding 
domain within the activated NMDA receptor ion channel. Access to such a site would be 
determined by the fractional open time of the channel and is thus consistent with the 
possibility of a guarded or transiently available [3H]dextrorphan binding site. In addition, 
the results of the present study indicate that specific [31-I]dextrorphan also has a slow rate of 
dissociation in the absence of exogenous glycine and glutamate in slide-mounted brain 
sections. These data are in agreement with previous reports demonstrating NMDA receptor 
agonist induced increases in both the association and dissociation rates of [3H]TCP (Kloog 
et al., 1988a; Bonhaus and McNamara, 1988; Kessler et al., 1989) and [311JMK-801 
( Kloog et al., 1988b; Komhuber et al., 1989) in well washed membrane preparations. 
Although binding kinetics are likely to be greatly influenced by specific assay 
conditions, if access to the NMDA receptor channel binding domain is a major hindrance 
noncompetitive antagonist binding, the time required for ligand association and dissociation 
with its binding site is likely to be longer in tissue that has been partly depleted of 
endogenous glycine and glutamate. Consistent with this possibility, kinetic studies have 
indicated that in the absence of exogenous NMDA agonists, [3111MK-801 and [3H]TCP 
also require a long time to reach equilibrium in extensively washed membrane homogenates 
(Kloog et al., 1988a,b; Komhuber et al., 1989; Johnson et al., 1989). Furthermore, slow 
association and dissociation rates have also been reported in quantitative autoradiographic 
studies of [3H]MK -801 binding to rat brain sections (Subramanian and McGonigle, 1991; 
Sakurai et al. 1991). 
We have previously shown that the magnitude of the increase in [31I]dextrorphan 
binding produced by exogenous glycine and glutamate in membrane homogenates 
dependent on the degree to which endogenous glycine and glutamate have been depleted 
from repetitively washed tissue (Franklin and Murray, 1992).  In a similar fashion, 
exogenously added NMDA receptor agonists have been reported to enhance both [31TITCP 124 
(Loo et al., 1986; Snell et al., 1987) and [3HJMK-801 (Foster and Wong, 1987; Reynolds 
et al., 1987) binding in extensively washed membrane homogenates. NMDA receptor 
agonist-induced increases in noncompetitive antagonist binding has proven to be more 
difficult to demonstrate directly by receptor autoradiography. Glutamate is the major 
neurotransmitter at excitatory synapses in the vertebrate central nervous system and is also 
a key amino acid in intermediary metabolism. It is not surprising, therefore, that rigorous 
washing procedures are required to lower concentrations of glutamate and other 
endogenous amino acids from brain tissue. The removal of endogenous glycine and 
glutamate from slide-mounted brain sections is especially difficult given the existence of 
diffusion barriers and because washing procedures have to be limited in the interests of 
preserving the anatomical integrity of the tissue section. Some investigators have instead 
employed indirect methods to observe NMDA receptor agonist-induced increases in 
noncompetitive antagonist binding by measuring binding in the presence of a competitive 
NMDA or glycine site antagonist (Bowery et al., 1988; Monaghan, 1991). Others have 
used non-equilibrium conditions to show large stimulations of binding by exogenously 
added agonists. In a report by Hosford et al. (1990), a 5 min incubation period was 
specifically chosen to demonstrate enhanced [3111TCP binding by glycine and NMDA. 
Non-equilibrium conditions may also have contributed to the large stimulations in [3H]MK­
801 binding observed by Fletcher and Bowery (1991), however, these investigators clearly 
demonstrated that the ability of glycine and glutamate to increase [3H}MK -801 binding 
could be altered by pre-washing the brain sections. In that study [3H]MK -801 binding in 
the stratum radiatum of the CAl region of the hippocampus was enhanced by glycine (10 
p.M) and glutamate (1 jiM) to 187 % of control levels following a 2 h pre-wash at room 
temperature. In the same study, the addition of glycine and glutamate following a 12 h pre­
wash enhanced [3H]MK -801 binding further to 285 % of control levels in the CAL 
Although some pre-washing procedure is usually employed prior to the 
autoradiographic study of NMDA receptor modulation, subtle variations in methodology 125 
are likely to produce variations in baseline levels of endogenous glycine and glutamate in 
the tissue sections. In particular, differences in section thickness, temperature of the buffer 
and the wash time may all contribute to the efficiency of the wash procedure and the final 
condition of the tissue sections. Nevertheless, in an autoradiographic study of [3H]MK­
801 binding by Sakurai et al. (1991) the apparent lack of stimulation of [3H]MK -801 
binding by added NMDA and glycine under equilibrium conditions was attributed to high 
residual levels of glycine and glutamate in the brain sections. Following a more rigorous 
pre-washing procedure, 100 pM NMDA was reported to enhance [3H]MK -801 binding in 
the stratum radiatum of the CA1 subfield of the hippocampus and molecular layer of the 
dentate gyrus by 181 % and 214 % respectively, whilst 100 11M glycine alone was reported 
to increase [31I]MK-801 binding 255 % in the molecular layer of the dentate gyrus (Sakurai 
et al., 1991). In another recent report by Subramanian and McGonigle (1993), washing 
was reported to have regionally specific stimulatory effects on [3H]MK -801 binding in the 
inner (III-V) layers of the frontoparietal cortex and the dorsolateral caudate putamen. 
Following our standard pre-wash procedure, specific [3H]dextrorphan binding in 
the stratum radiatum of CAl was modestly enhanced (20 - 35 %) by glutamate and 
unstimulated by glycine under equilibrium conditions.  In contrast to the reports of 
[3H]MK -801 binding mentioned above, this profile was basically unchanged by  a 
prolonged washing procedure designed to lower endogenous levels of glycine and 
glutamate in the tissue sections. The study of other brain areas revealed the same pattern; 
[31]dextrorphan binding was not significantly enhanced by exogenously added glycine or 
glutamate in the molecular layer of the dentate gyrus, outer (II-DI) and inner (IV-VI) layers 
of the frontoparietal cortex or the lateral thalamic nuclei following standard or prolonged 
pre-washing of the tissue sections. In light of the fact that we were able to detect a 
substantial increase in the association rate of [31-I]clextrorphan by the addition of glycine 
(100 MM) and glutamate (1 pM) to the incubation droplet, it seems unlikely that saturating 
concentrations of the endogenous agonists are still present following our prolonged pre­126 
wash procedure.  It therefore appears that [3H]dextrorphan is far less sensitive to the 
modulatory effects of glycine and glutamate than [311]MK-801. 
The relative insensitivity of [31-I]dextrorphan binding to glycine and glutamate may 
be provisionally explained by the possible existence of a [3H]dextrorphan binding site that 
to some degree is nonidentical with the binding sites of [3H]TCP and [31-1]MK-801, rather 
than the unique regulation of [3H]dextrorphan at a common noncompetitive antagonist 
binding site. The concept of multiple noncompetitive NMDA antagonist sites with affinity 
for this general class of drug, rather than the existence of a single binding site for all 
members of this drug class, has been suggested previously to explain the interaction of 
desipramine and MK-801 with NMDA receptors (Serganor et al., 1989). It has recently 
been proposed that the dissociative anaesthetic binding site may be located in the vestibule 
of the NMDA channel pore and that the NMDA channel must be gated open before this 
binding site is exposed (MacDonald et al., 1991). Channel closure subsequent to the 
binding of a dissociative anaesthetic molecule, such as MK-801, ketamine or PCP, results 
in the trapping of the blocker within the closed channel (MacDonald et al., 1991). It is 
therefore possible that the apparent indifference of [3H]dextrorphan binding, to the 
presence of glycine and glutamate, is a consequence of its occupation of a more 
superficially located binding site, perhaps in the vestibule of the NMDA receptor ion 
channel, that is less sensitive to channel opening and closing. As a consequence 
[3H]dextrorphan binding may be less dependent on agonist activation of the receptor. 
Recent attempts to identify the location of a noncompetitive antagonist binding 
domain within the NMDA receptor channel have utilised recombinant DNA techniques. All 
known NMDA receptor subunits have an asparagine residue in their putative channel-
forming second membrane-dwelling segment at a site that is homologous to the glutamine-
arginine editing position (Q/R site) of -the AMPA-kainate receptors (Nakanishi, 1992). 
Certain non-NMDA subunits possess a glutamine at the Q/R site, whilst others carry an 
arginine residue that appears to be a critical determinant of Ca2+ permeability. This 127 
arginine residue is not encoded in the subunit gene but is generated by an RNA editing 
process.  Site-directed mutagenesis has revealed that substitution of this conserved 
asparagine residue in an NMDA receptor subunit, to glutamine or arginine reduces the 
sensitivity of NMDA receptor channels to blockade by MK-801 (Mori et al., 1992; 
Sakurada et al., 1993). In a study by Kawajiri and Dingledine (1993), mutation of the 
same asparagine of NMDAR1 to an arginine residue resulted in a 200-fold reduction in the 
potency of TCP to block heteromeric NMDA receptors and abolished the use-dependent 
nature of the blockade. Furthermore, in support of the idea that noncompetitive antagonists 
may have more than one site of action on the NMDA receptor channel, these authors also 
reported a lower affinity, non use-dependent component of the blockade by TCP that was 
retained in the mutant receptor. Although the conserved asparagine residue in the second 
membrane-dwelling region of NMDA receptor subunits appears to influence calcium 
permeability and Mg2+ blockade of the channel (Mori et al., 1992; Burashev et al., 1992) 
as well as noncompetitive antagonist binding, it has recently been proposed that the 
contribution of this residue may differ for various noncompetitive antagonists (Yamakura et 
al., 1993). In a comparison of four heteromeric murine NMDA receptors, wild-type 
NMDA receptor channels differed in their sensitivity to blockade by MK-801. In the same 
study, mutation of the asparagine residue reduced the sensitivity of NMDA receptor 
channels to blockade by PCP, ketamine and SKF-10,047 to different extents. These 
findings are not incongruous with our positing of nonidentical sites with respect to 
noncompetitive antagonist binding. 
Further evidence for a difference in the nature of noncompetitive antagonism of 
NMDA-mediated responses by dextrorphan and MK-801 has been provided by 
electrophysiologic data (Cole et al., 1989). Unlike MK-801, which was found to act in 
clearly use-dependent manner, dextrorphan showed no evidence of use-dependency in 
producing a potent, dose-dependent and selective noncompetitive inhibition of NMDA-
mediated depolarization in the rat hippocampal slice (Cole et al., 1989). These findings 128 
are not inconsistent with the possibility of dextrorphan gaining access to a site within the 
ion channel domain that is relatively exterior to that of MK-801 and whichmay therefore be 
less influenced by the state of the channel. Consistent with this possibility, the onset of 
dextrorphan blockade has been shown to progress slowly but completely in the 
hippocampal slice in the absence of exogenous agonist or evoked excitation; in contrast, 
onset of MK-801 blockade fails to progress under these closed channel conditions 
indicating a high degree of use-dependence (Cole et al., 1989).  In addition to the 
differential sensitivity of dextrorphan and MK-801 to glycine and glutamate, the more rapid 
kinetics of channel blockade by dextrorphan may also contribute to its lack of use-
dependency. The particularly slow time course and long duration of blockade of the 
NMDA receptor channel by MK-801 is thought to be related to its high degree of use-
dependency (Wong et al., 1986). 
Although [3H] dextrorphan binding appears to be regulated in a distinctive manner 
by glycine and glutamate, the presence of both agonists is still required for binding to 
occur. Consistent with a dependence of [3H]dextrorphan binding upon activation of the 
NMDA receptor-complex, basal specific binding was sensitive to D-AP5, a competitive 
NMDA antagonist, and 7-clorokynurenic acid, a strychnine-insensitive glycine antagonist. 
Following standard pre-wash conditions in the absence of exogenous glycine and 
glutamate, specific [3H]dextrorphan binding was completely inhibited by the presence of 
the either antagonist in a concentration dependent manner. These data confirm our previous 
findings in membrane homogenates (Franklin and Murray, 1992) and thus lend further 
support for a relationship between [3H]dextrorphan binding and activation of the NMDA 
receptor complex. These data are also consistent with our demonstration of glutamate and 
glycine augmentation of the [3H]dextrorphan association rate in brain sections. The ability 
of 7-clorokynurenic acid and D-AP5 to inhibit [3H]dextrorphan binding is therefore a result 
of their competitive surmounting of the activation of NMDA receptors by endogenous 
glutamate and glycine. 129 
The present fmdings are also in agreement with the results of other autoradiographic 
studies which have used different radioligands to visualize the NMDA receptor. Complete 
inhibition of specific [3H]MK -801 binding has been reported in the presence of D-AP5 
(Bowery et al., 1988; Sakurai et al., 1991; Beaton et al., 1992) and in the presence of 7­
clorokynurenic acid (Sakurai et al., 1991; Sakurai et al., 1993; Taconi et al., 1993). In 
addition, D-AP5 will afford complete inhibition of both specific [3H]TCP (Hosford et al., 
1990) and NMDA-sensitive [3H]glutamate (Greenamyre et al., 1985; Beaton et al., 1992) 
binding. 
Recent evidence has suggested that regionally distinct populations of NMDA 
receptors can be distinguished autoradiographically on the basis of inhibition of binding by 
competitive and noncompetitive NMDA receptor antagonists (Beaton et al., 1992; Sakurai 
et al., 1993). It is interesting in this context that [3H]dextrorphan binding was inhibited by 
7-chlorokynurenic acid with similar potency in the brain areas that we studied, yet the 
competitive antagonist D-AP5 showed a more marked variation in its potency to inhibit 
[3H]dextrorphan binding over the same areas. Furthermore, regional distinctions in the 
inhibition of [3H]dextrorphan binding by D-AP5 did not follow the same patterns reported 
for inhibition of [311]MK-801 binding by the competitive NMDA antagonist 3-(2­
carboxypiperazin-4-y1)-propy1-1-phosphonic acid (CPP) (Beaton et al., 1992; Sakurai et 
al., 1993). Inhibition of [3H]dextrorphan binding by D-AP5 seems to distinguish a distinct 
population of sites that are weakly inhibited by D-AP5 in the lateral thalamic nuclei. Buller 
et al. (1994) have recently shown that populations of receptors displaying high affinity for 
[3H]CPP, typified by the lateral thalamus, are localized to brain regions expressing high 
densities of NMDAR2A (NR2A) mRNA but not NR2B mRNA. The ratio of NR2A to 
NR2B mRNA is greater in cortex than lateral thalamus (Buller et al., 1994); thus,  a 
preponderance of the NR2A subunit may confer the much higher affinity of D-AP5 for 
[3H]dextrorphan binding sites in this area relative to lateral thalamus. It is also interesting 
to note that the lateral thalamus and cortex have previously been distinguished from other 130 
brain areas in that [3H]MK -801 binding appears to be less sensitive to stimulation by L-
glutamate in these regions (Monaghan, 1991). 
At this point the possibility of regional differences in the concentration of 
endogenous glutamate should not be ruled out as a potential source of variation in the 
relative potencies of [3H]dextrorphan inhibition by D-AP5. It seems unusual, however, 
that endogenous factors would not also differentially influence the effects of 7­
chlorokynurenic acid in the same experimental paradigm. At present the wide variations in 
methodology permit only general comparison of our findings with other reported NMDA 
receptor populations distinguished by this kind of autoradiographic study. The binding 
profile of [3H]dextrorphan, however, is clearly different from that reported for [311]MK­
801 (Sakurai et al., 1993).  Given the increasing evidence for NMDA receptor 
heterogeneity, it would not be unreasonable to expect different combinations of subtypes to 
also differ with respect to both their competitive and noncompetitive antagonist 
pharmacology. 
Of relevance to the problem of residual glycine and glutamate in slide-mounted 
sections, our study of [3H]dextrorphan binding in the presence of D-AP5 and 7­
clorokynurenic acid also confirms that after our standard pre-wash conditions, in a large 
volume of 5 mM HEPES (pH 7.4) at 20°C for 3 x 20 min, endogenous glutamate is 
certainly not removed from the 16 pm sections entirely. In a recent study by Jaarsma et al. 
(1993), the concentration of residual glutamate was measured in 15 pin sections that had 
been pre-washed in 50 mM Tris-HCL buffer (pH 8.0) for 3 x 20 min at room temperature. 
Following a 1 h incubation at 2°C with incubation buffer alone, a free L-glutamate 
concentration of 42 ± 4 nM was detected in the 300 gl incubation droplet. Although in our 
own studies we routinely use a larger incubation droplet (430 p1) to help lower the free 
glutamate concentration and guard against ligand depletion, it is likely that at least this much 
glutamate will leak from the section following a 4 h incubation period at room temperature. 
Since D-AP5 and 7-chlorokynurenic acid were able to completely inhibit basal 131 
[3H]dextrorphan binding, the endogenous agonists must certainly be present at a 
concentration sufficient for NMDA receptor activation to occur. 
The rank order of potencies of an array of noncompetitive NMDA receptor 
antagonists tested in the present study as inhibitors of [3H]dextrorphan binding in the 
stratum radiatum of the CA1 subfield of the hippocampus and the outer layers of the 
frontoparietal cortex, is in accordance with the pharmacologic profile for the NMDA 
receptor site labelled by [3H]dextrorphan in membrane homogenates prepared from rat 
forebrain (Franklin and Murray, 1992). These competition data provide additional 
evidence that the site labelled by [3H]dextrorphan in slide-mounted sections is localized to a 
noncompetitive antagonist domain of the NMDA receptor-channel complex. In contrast to 
our findings in membrane homogenates, all compounds recognized a single high-affinity 
[3H]dextrorphan binding site in both the stratum radiatum of CA1 and the outer cortical 
layers.  Although quantitative receptor autoradiography permits the pharmacologic 
characterization of discrete brain regions, long postincubation wash periods such as the one 
employed in the present study may not permit detection of lower affinity [3H]dextrorphan 
binding sites in slide-mounted tissue. 
In accordance with pharmacologic signature of sites labelled by [3H]PCP (Murray 
and Leid, 1984) and [3H]dextrorphan (Franklin and Murray, 1992) in rat brain 
membranes, dextromethorphan was less potent than dextrorphan as a competitor for 
[3H]dextrorphan binding sites in slide-mounted sections. The rapid metabolism of 
dextromethorphan to dextrorphan following its peripheral administration (Barnhart, 1980) 
is often a complicating factor in the interpretation of many experimental models of NMDA 
antagonism by dextromethorphan in vivo. Craviso and Musacchio (1983a), however, 
found no evidence for dextromethorphan metabolism in brain microsomes in vitro and it is 
therefore unlikely that the binding properties of dextromethorphan in vitro are confounded 
by the presence of dextrorphan. Whilst showing complete efficacy for [3H]dextrorphan 
binding sites in the stratum radiatum of the CA1 region of the hippocampus and the outer 132 
layers of the frontoparietal cortex, dextromethorphan was over 6-fold less potent than 
dextrorphan in the CAl and approximately 30-fold less potent than in the outer cortical 
layers. Given the recent evidence for differential sensitivity of recombinant heteromeric 
receptors to block by MK-801 (Yamakura et al., 1993), it is intriguing to speculate that the 
wide variation in relative potencies of dextrorphan and dextromethorphan for sites labelled 
by [3H]dextrorphan may reflect differences in the properties of native NMDA receptors 
located in the stratum radiatum of CAl and the outer frontoparietal cortex. 
[3H]Dextrorphan binding sites are heterogeneously distributed throughout the rat 
brain with a marked anatomical specificity that unambiguously corresponds to the known 
distribution of NMDA receptors. Equilibrium saturation binding data from several brain 
areas confirms the presence of a differential distribution of recognition sites and suggests 
that [3H]dextrorphan binds to a single population of high affinity sites under the assay 
conditions employed. Since the KD values of these binding sites do not vary significantly, 
the regional heterogeneity of [3H]dextrorphan binding sites, as determined by single 
[3H]dextrorphan concentration equilibrium binding values, can be regressed to differences 
in the absolute receptor densities in the regions evaluated. 
The highest levels of [3H]dextrorphan binding were found in the stratum radiatum 
and stratum oriens of the CAl subfield of the hippocampus. These areas correspond to the 
target zones of ipsilateral and commisural axons of glutamatergic pyramidal neurones 
originating in the CA3 region of the hippocampus.  In contrast, low levels of 
[3H]dextrorphan binding were found in the stratum pyramidale of hippocampal region CAl 
corresponding to the pyramidal cell body layer of this area. Similarly, low levels of 
binding were detected in the stratum pyramidale and stratum lucidum of area CA3, 
representing the target zones of mossy fibres which are thought to have low densities of 
NMDA receptors (Cotman et al., 1987). The granule cell layer of the dentate gyrus, which 
contains the densely packed cell bodies of granule cell neurones, was virtually devoid of 
specific [311]dextrorphan binding. The molecular layer of the dentate gyrus, however, 133 
displayed high levels of binding presumably corresponding to NMDA receptors located on 
the apical dendrites of pyramidal cells which form synaptic connections with input fibres 
from the perforant pathway. The outer layers of the cerebral cortical regions also displayed 
moderate to high levels of [3H]dextrorphan binding consistent with the dense populations 
of NMDA receptors located in cortical layers I to III (Cotman et al., 1987). Somewhat 
lower densities of [3H]dextrorphan binding were detected in the striatum and lateral 
thalamic nuclei. 
The relative distribution of [3H]dextrorphan binding sites in rat forebrain is 
consistent with the reported distribution of NMDA-sensitive [3H]glutamate binding sites 
(Greenamyre et al.,  1985; Monaghan and Cotman, 1985).  Furthermore, the 
autoradiographic pattern of [3H]dextrorphan binding sites in the forebrain is in excellent 
agreement with previously reported distributions of [3H]MK -801 (Bowery et al., 1988; 
Subramaniam and McGonigle, 1991; Sakurai et al., 1991) and [3H]TCP (Gundlach et al., 
1986; Maragos et al, 1988) binding sites. As the relative distribution of [3H]dextrorphan 
binding sites in rat brain bears no resemblance to the previously reported distributions of 
[3H]dextromethorphan binding sites in rat or guinea pig brain (Canon et al., 1989; Torte lla 
et al., 1989), it appears that [3H]dextrorphan binding sites are unrelated to 
[311]dextromethorphan or sigma binding sites. These data lend further support for a 
distinct pharmacology of dextromethorphan that is unrelated to its affinity for a 
noncompetitive antagonist domain of the NMDA receptor. 
One brain area where the relative distribution of [3H]dextrorphan binding sites does 
not match the reported pattern of sites labelled by either NMDA-sensitive [314]glutamate, 
[311]MK-801 or [3H]TCP is in the cerebellum. [3H]Dextrorphan binds with a 3-fold 
greater density to the molecular layer of the cerebellum than the granule cell layer. 
Although a large percentage of glutamate receptors in the molecular layer of the cerebellum 
are thought to be of the non-NMDA receptor subtype, a population of NMDA-sensitive 
[3H]glutamate binding sites is certainly present in this brain area. Greenamyre et al. (1985) 134 
reported that 25-30 % of [3H]glutamate binding in the molecular layer of the cerebellum 
could be inhibited by NMDA receptor-specific agents. Monaghan and Cotman (1985) also 
detected NMDA-sensitive binding in the molecular layer of the cerebellum that was 
approximately 25 % of that seen in the granule cell layer. Furthermore, autoradiographic 
visualization of [3H]PCP binding sites by Quirion et al. (1981) in the rat brain revealed 
preferential labelling of the molecular layer of the cerebellum. The discovery that [3H]TCP 
preferentially binds to the granule cell layer of the cerebellum gave an early indication of 
potential differences in the binding properties of [3H]PCP and [3H]TCP in the cerebellum 
and led to the proposal that the two ligands had differing anatomical specificities (Vignon et 
a., 1986). It is possible, therefore, that the high density of [3H]dextrorphan binding sites 
in the molecular layer of the cerebellum, and possibly those sites labelled by [3H]PCP 
(Quirion et al., 1981), correspond to autoradiographic localization of NMDA receptors at 
excitatory synapses on the dendrites of Purkinje cells in this brain region. 
Immunocytochemistry has recently revealed NMDAR1 specific labelling of Purkinje cell 
dendrites in the molecular layer of the cerebellar cortex (Brose et al., 1993). Furthermore, 
in situ hybridization studies have localized NMDAR1 mRNA in Purkinje cell bodies of 
adult rat cerebellum (Moriyoshi et al., 1991; Laurie and Seeburg, 1994a). 
A consensus of electrophysiological and binding data provide evidence for NMDA 
receptors in the cerebellum that are pharmacologically distinct from those in forebrain. 
Cerebellar NMDA receptors have been shown to differ with respect to their responses to 
regulation via the glycine and glutamate modulatory domains of the NMDA receptor 
(Monaghan, 1988; Monaghan and Beaton, 1991; Priestly and Kemp, 1993). In addition, 
these receptors appear to have a relatively low affinity for MK-801 (Quarum et al., 1990; 
Ebert et a., 1991; Beaton et al., 1992) and TCP (Vignon et al., 1986; Maurice and Vignon, 
1990). Receptor autoradiography of the cerebellum has revealed that NMDA-sensitive 
[3H]glutamate binding is predominantly found in the granule cell layer (Greenamyre et al., 
1985; Monaghan and Cotman, 1985). In accordance with this distribution, [3H]TCP 135 
binding sites predominate in the granule cell layer of the cerebellum (Gundlach et al., 1986; 
Vignon et al., 1986) but have been reported to be much fewer than those sites labelled by 
NMDA-displaceable [3H]glutamate (Maragos et al, 1988) or the competitive NMDA 
antagonist [3H]CPP (Jarvis et al., 1987). Similarly, low levels of [3H]MK -801 binding 
have been reported in the granule cell layer of the cerebellum (Subramaniam and 
McGonigle, 1991; Beaton et al., 1992); in some studies, however, the low affinity of MK­
801 for cerebellar NMDA receptors has been offered as an explanation for the fact that 
[311]MK-801 binding can not be detected in the cerebellum by receptor autoradiography 
(Bowery et al., 1988; Monaghan, 1991; Sakurai et al., 1991). Support for the idea of 
regional heterogeneity amongst native NMDA receptors is also provided by data derived 
from the study of recombinantly expressed heteromeric NMDA receptors. Given that 
mRNAs encoding specific splice variants of NR1 (Laurie and Seeburg, 1994a) and 
particular subunits of NR2, (E3 / NR2C) (Kutsuwada et al., 1992; Monyer et al., 1992) are 
predominantly found in the cerebellum, it would not be unreasonable to expect variance in 
subunit composition to underlie pharmacologic differences in native cerebellar NMDA 
receptors. 
The regional distribution of [3H]dextrorphan binding sites clearly distinguishes 
[3H]dextrorphan sites from those sites labelled by [3H]MK -801  or [3H]TCP in the 
cerebellum lending further support for regional heterogeneity amongst native NMDA 
receptors. We have previously identified differences in populations of NMDA receptors 
labelled by [3H]dextrorphan in rat forebrain and cerebellum (Franklin and Murray, 1992). 
In slide-mounted sections dextrorphan was a less potent inhibitor of [31I]dextrorphan 
binding in the molecular and granule cell layers of the cerebellum than in forebrain regions. 
[311]Dextrorphan labels high and low affinity sites in forebrain and cerebellar membranes, 
however, a larger fraction of sites in the cerebellum are of low affinity. Although we are 
unable to resolve two [31I]dextrorphan affinity states in slide-mounted tissue this low 
affinity population of sites may contribute to the reduced potency reported herein. Further 136 
support for a distinction between forebrain and cerebellar [3H]dextrorphan binding sites is 
provided by the fact that MK-801 was an ineffective competitor for [3H]dextrorphan sites 
in the cerebellar molecular and granule cell layers. It is interesting to note that in an in vivo 
study in the mouse, Maurice and Vignon (1990) found MK-801 to be the most potent 
inhibitor of [3H]TCP binding in the cerebrum and hippocampus but an ineffective 
competitor for [3H]TCP binding sites in cerebellum. These observations may be indicative 
of some degree of non-identity between the low affinity MK-801 and TCP recognition sites 
in the cerebellum and provide additional confirmation of the unsuitability of MK-801 to 
define nonspecific [3H]dextrorphan binding in this brain region. 
In summary, the anatomical distribution of [3H]dextrorphan recognition sites in rat 
forebrain corresponds to the known distribution of NMDA receptors labelled by NMDA-
sensitive [3H]glutamate, [3H]MK -801 and [3H]TCP. Furthermore, the pharmacologic 
profile of these binding sites is consistent with an association of [3H]dextrorphan with a 
noncompetitive antagonist domain of the NMDA receptor-channel complex. We have, 
however, identified both regional and pharmacologic heterogeneity in the binding 
characteristics of [3H]dextrorphan which appears to reflect some degree of nonidentity 
between [3H]dextrorphan binding sites and those sites labelled by other noncompetitive 
antagonists. Given the increasing evidence for NMDA receptor heterogeneity, ligand 
autoradiography represents a powerful technique with the potential to selectively identify 
distinct populations of native NMDA receptors. 
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Chapter 6 
Discussion 
The pharmacologic properties of the dextrorotatory morphinans, dextrorphan and 
dextromethorphan, have been studied since the early 1950s when they became widely used 
as antitussive agents. Dextromethorphan is now marketed as a safe and effective non­
prescription cough suppressant in more than sixty countries under many different 
proprietary names. More recently, however, dextrorphan and dextromethorphan have been 
shown to have anticonvulsant and neuroprotective properties by virtue of their activity as 
noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) subfamily of ionotropic 
glutamate receptors. The aim of this research project was to gain a better understanding of 
the interaction of dextrorotatory opioids with the NMDA receptor-operated ion channel. 
Initial studies were undertaken in the whole animal to specifically investigate the 
anticonvulsant and psychoactive effects of dextrorphan and dextromethorphan. Later 
studies were done in vitro, using radiolabelled dextrorphan to determine the anatomical 
distribution of dextrorphan binding sites in the rat brain by quantitative receptor 
autoradiography. Although the NMDA receptor is the most thoroughly characterized of the 
glutamate receptors with respect to its pharmacology and physiology, the cloning of the 
first NMDA-gated ion channel was not accomplished until the end of 1991 (Moriyoshi et 
al., 1991). It is hoped that a more complete mechanistic understanding of the function of 
native NMDA receptors will eventually allow this receptor system to be better manipulated 
for therapeutic gain in the treatment of epilepsy and to reduce neuronal injury associated 
with stroke, head trauma, sustained convulsions and hypoglycaemia. 
Although the anticonvulsant activity of dextrorphan and dextromethorphan has been 
documented and is comparable to that of other noncompetitive NMDA antagonists, the 138 
underlying mechanism of action has remained less certain. The rapid 0-demethylation of 
dextromethorphan to dextrorphan following peripheral administration, has been a 
complicating factor in the interpretation of some studies in vivo. The ability of dextrorphan 
and dextromethorphan to suppress convulsions was therefore assessed using an animal 
model in which generalized motor seizures can be generated by unilateral focal injection of 
a chemoconvulsant in the rat prepiriform. In this model, test compounds are also delivered 
to the same locus of the prepiriform cortex by direct intracerebral administration thereby 
limiting dispositional influences.  The anticonvulsant efficacy of dextrorphan and 
dextromethorphan in the prepiriform cortex was comparable to that of the noncompetitive 
NMDA antagonists phencyclidine (PCP) and MK-801. Furthermore, the anticonvulsant 
potencies of the compounds tested were highly correlated with their respective affinities for 
the [3H]dextrorphan- labelled NMDA receptors in rat forebrain membrane preparations 
(Franklin and Murray, 1992). The correlation of this pharmacological profile with that 
defined by [31I]dextrorphan equilibrium competition binding studies suggests that 
interaction with the NMDA receptor cation channel complex mediates the anticonvulsant 
actions of the dextrorotatory opioids. 
Whilst investigating the anticonvulsant effects of the dextrorotatory opioids in the 
prepiriform cortex, a novel anticonvulsant action of 1,3-di(2-tolyl)guanidine (DTG) was 
discovered. This compound was initially included as a reference sigma (a) compound in 
these studies and was therefore predicted to have little effect. DTG, however, was a potent 
and efficacious anticonvulsant in the rat prepiriform cortex by a mechanism that does not 
involve a receptors. Noncompetitive antagonism of NMDA receptor-mediated excitation at 
the MK-801 / PCP binding site is also unlikely to account for the protective effects of 
DTG. 
Although devoid of morphine-like effects and consequently considered non­
addictive (Isbell and Fraser, 1953), the dextrorotatory morphinans, at levels exceeding the 
recommended antitussive dose, can induce a PCP-like syndrome. Dextrorphan and 139 
dextromethorphan were found to induce a stereotyped behavioural response in rats that was 
indistinguishable from that produced by PCP and other noncompetitive NMDA 
antagonists.  The correlation of this pharmacologic profile with that defined by 
[311]dextrorphan equilibrium competition binding studies suggests that interaction with the 
NMDA receptor-channel complex mediates the stereotyped behavioural effects of these 
compounds. 
To specifically address the propensity of dextromethorphan to induce these 
behaviours, dextrorotatory opioid-induced stereotypies were compared in female Sprague-
Dawley and female Dark Agouti rats. The female Dark Agouti rat lacks cytochrome P450 
2D1 which catalyses the 0-demethylation of dextromethorphan to dextrorphan. Therewere 
no differences in either the potencies or time to peak effect of dextrorphan and 
dextromethorphan to induce stereotyped behaviour in either of the two rat strains. These 
data suggest that the affinity of dextromethorphan for NMDA receptors adequately accounts 
for its ability to induce stereotyped behaviour. 
In order to determine the functional significance of various combinations of 
recombinant NMDA receptor subunits and splice variants, there is an increasing need for a 
better understanding of the regional distribution and properties of native NMDA receptors. 
Receptor autoradiography has provided evidence for regionally heterogeneous populations 
of native NMDA receptors in the rat forebrain based on differential activation of the NMDA 
receptor-channel complex by [3H]glutamate, binding of the competitive glutamate 
antagonist [311]3-(2-carboxypiperazin-4-y1)-propy1-1-phosphonic acid ([3H]CPP)  or 
regulation of [3H]MK -801 binding by NMDA receptor agonists and antagonists 
(Monaghan et al., 1988; Monaghan 1991; Beaton et al., 1992; Sakurai et al., 1993). In 
addition, a pharmacologically distinct NMDA receptor has been identified in the cerebellum 
that appears to have, as one of its characteristics, a particularly low affinity for MK-801 
(Maurice and Vignon 1990; Quarum et al., 1990; Ebert et al., 1991; Beaton et al., 1992). 140 
Previous studies indicate that [3H]dextrorphan labels a high affinity site in rat brain 
membranes corresponding to the noncompetitive antagonist binding domain of the NMDA 
receptor-channel complex (Franklin and Murray, 1990; 1992). However, the binding 
domain of [3H]dextrorphan may not be identical to the channel binding sites of either 
[3H]MK-801 or [3H]141-(2-thienyl)cyclohexyl]piperidine ([3H]TCP). Specific aspects of 
the regulation of [3H]dextrorphan binding by modulators of the NMDA receptor-channel 
complex distinguish it from [3H]MK-801 and [3H]TCP and may be indicative of 
underlying differences in the mechanisms of their noncompetitive antagonism. 
[3H]Dextrorphan may therefore represent a unique ligand for the NMDA receptor that could 
facilitate the identification of functionally and regionally distinct populations of native 
NMDA receptors. 
[3H]Dextrorphan binding sites were characterized in slide-mounted rat brain 
sections and their regional distribution ascertained using quantitative receptor 
autoradiography. These studies extend our previous fmdings in membrane homogenates 
(Franklin and Murray, 1990; 1992) in that [3H]dextrorphan appears to selectively label a 
high affinity site localized within an open channel domain of the NMDA receptor. The 
[3H]dextrorphan binding site may not, however, be identical to ion channel binding sites 
labelled by other noncompetitive antagonists. Specifically, differences in the regulation of 
[3H]dextrorphan binding by glycine and glutamate and the labelling of high affinity sites in 
the cerebellum distinguish [3H]dextrorphan binding from that of either [3H]MK-801 or 
[3H]TCP. 
The kinetics of association and dissociation of [3H]dextrorphan with its binding site 
are slow in slide-mounted brain sections. The addition of glycine and glutamate, however, 
increases the apparent association rate of [3H]dextrorphan, presumably a result of their 
ability to facilitate access of [3H]dextrorphan to a guarded or transiently available binding 
domain within the activated NMDA receptor ion channel.  In contrast to reports of 
[3H]MK -801 binding in slide-mounted sections (Fletcher and Bowery, 1991; Sakurai et 141 
al., 1991), we were unable to demonstrate agonist-induced increases in [3H]dextrorphan 
binding following a prolonged washing procedure designed to lower endogenous levels of 
glycine and glutamate in the sections. As the addition of glycine and glutamate produced a 
substantial increase in the association rate of [311]dextrorphan following standard pre-
washing conditions, it seems unlikely that saturating concentrations of the endogenous 
agonists are still present following prolonged pre-washing. Together with our previous 
fmdings in membrane homogenates (Franklin and Murray, 1992), these data suggest that 
[3H]dextrorphan is less sensitive to the modulatory effects of glycine and glutamate than 
[3H]MK -801. Although it would be premature at this point to attempt to assign a 
functional significance to our observations, the relative insensitivity of [3H] dextrorphan 
binding to glycine and glutamate may provisionally be explained by the possible existence 
of a [3H]dextrorphan binding site that to some degree is nonidentical to the binding site of 
[3H]MK -801, rather than the unique regulation of [3H]dextrorphan  at a common 
noncompetitive antagonist binding site. The apparent indifference of dextrorphan to the 
presence of glycine and glutamate may be a consequence of its occupation of a more 
superficially located binding site than that of MK-801 that is less dependent on agonist 
activation of the receptor. 
Although [3H]dextrorphan binding appears to be regulated in a distinctive manner 
by glycine and glutamate, the presence of both agonists is still required for binding to 
occur. Basal specific [3H]dextrorphan binding was sensitive to D-AP5, a competitive 
NMDA antagonist, and 7-clorokynurenic acid, a strychnine-insensitive glycine antagonist, 
presumably a result of their competitive surmounting of the activation of NMDA receptors 
by endogenous glutamate and glycine. Interestingly, D-AP5 showed a marked regional 
variation in its potency to inhibit [3H]dextrorphan binding which did not follow patterns 
previously reported for inhibition of [3H]MK -801 binding by CPP (Beaton et al., 1992; 
Sakurai et g., 1993). In particular, a distinct population of [3H]dextrorphan binding sites 
was weakly inhibited by D-AP5 in the lateral thalamus. Buller et al. (1994) have recently 142 
shown that populations of receptors displaying high affinity for [3H]CPP, typified by the 
lateral thalamus, are localized to brain regions expressing high densities of NMDAR2A 
(NR2A) mRNA but not NR2B mRNA. The ratio of NR2A to NR2B mRNA is greater in 
cortex than lateral thalamus (Buller et al., 1994); thus, a preponderance of the NR2A 
subunit may confer the much higher affinity of D-AP5 for [311]dextrorphan binding sites in 
this area relative to lateral thalamus. 
The rank order of potencies of an array of noncompetitive NMDA receptor 
antagonists as inhibitors of [3H]dextrorphan binding in CA1 and outer cortex, provide 
additional evidence that the site labelled by [3H]dextrorphan in slide-mounted sections is 
localized to a noncompetitive antagonist domain of the NMDA receptor. In accordance 
with the pharmacologic signature of sites labelled by [3H]PCP (Murray and Leid, 1984) 
and [3H]dextrorphan (Franklin and Murray, 1992) in brain membranes, dextromethorphan 
was less potent than dextrorphan as a competitor for [3H]dextrorphan binding sites in slide-
mounted sections. Given recent evidence for differential sensitivity of recombinant 
heteromeric receptors to block by MK-801 (Yamakura et al., 1993), variation in the relative 
potencies of dextrorphan and dextromethorphan for sites labelled by [3H]dextrorphan may 
reflect differences in the properties of native NMDA receptors located in CAl and outer 
cortex. 
[3H]Dextrorphan binding sites are heterogeneously distributed throughout the rat 
brain with a marked anatomical specificity that unambiguously corresponds to the known 
distribution of NMDA receptors (Cotman et al., 1987). Equilibrium saturation binding data 
from several brain areas confirms the presence of a differential distribution of recognition 
sites and suggests that [3H]dextrorphan binds to a single population of high affinity sites 
under the assay conditions employed. Since the KD values of these binding sites do not 
vary significantly, the regional heterogeneity of [311]dextrorphan binding sites, as 
determined by single [3H]dextrorphan concentration equilibrium binding values, can be 
regressed to differences in the absolute receptor densities in the regions evaluated. 143 
The relative distribution of [3H]dextrorphan binding sites in rat forebrain is 
consistent with the reported distribution of NMDA-sensitive [3H]glutamate binding sites 
(Greenamyre et al.,  1985; Monaghan and Cotman, 1985).  Furthermore, the 
autoradiographic pattern of [3H]dextrorphan binding sites in the forebrain is in excellent 
agreement with previously reported distributions of [3H]MK -801 (Bowery et al., 1988; 
Subramaniam and McGonigle, 1991; Sakurai et al., 1991) and [3H]TCP (Gundlach et al., 
1986; Maragos et al, 1988) binding sites. As the relative distribution of [3H]dextrorphan 
binding sites in rat brain bears no resemblance to the previously reported distributions of 
[3H]dextromethorphan binding sites in rat or guinea pig brain (Canoll et al., 1989; Torte lla 
et al., 1989), it appears that [3H]dextrorphan binding sites are unrelated to either 
[3H]dextromethorphan binding sites or sigma binding sites (Walker et al., 1990). These 
data lend further support for a distinct pharmacology of dextromethorphan that is unrelated 
to its affinity for the noncompetitive antagonist domain of the NMDA receptor. 
One brain area where the relative distribution of [3H]dextrorphan binding sites does 
not match the reported pattern of sites labelled by either NMDA-sensitive [3H]glutamate, 
[3H]MK -801 or [3H]TCP is the cerebellum. The density of [3H]dextrorphan sites in the 
cerebellar molecular layer exceeds that of the granule cell layer by a factor of three. 
Receptor autoradiography of the cerebellum has revealed NMDA-sensitive [3H]glutamate 
binding predominantly in the granule cell layer (Greenamyre et al., 1985; Monaghan and 
Cotman, 1985). In accordance with this distribution, [3H]TCP binding sites predominate 
in the granule cell layer ( Gundlach et al., 1986; Vignon et al., 1986) but have been reported 
to represent a much lower density of sites than those labelled by NMDA-displaceable 
[311]glutamate (Maragos et al, 1988) or [3H]CPP (Jarvis et al., 1987). Similarly, low 
levels of [3H]MK -801 binding have been reported in the granule cell layer (Subramaniam 
and McGonigle, 1991; Beaton et al., 1992); in some studies, however, the low affinity of 
MK-801 for cerebellar NMDA receptors has been offered as an explanation for the fact that 
[3H]MK -801 binding is frequently undetected in the cerebellum by  receptor 144 
autoradiography (Bowery et a., 1988; Monaghan, 1991; Sakurai et a1.,1991). 
Although non-NMDA receptors are thought to predominate in the cerebellar 
molecular layer, a population of NMDA-sensitive [3H]glutamate binding sites is certainly 
present in this brain area (Monaghan and Cotman, 1985). Greenamyre et al. (1985) also 
reported 25-30 % of [3H]glutamate binding in the molecular layer of the cerebellum could 
be inhibited by NMDA receptor-specific agents.  Furthermore, autoradiography of 
[3H]PCP binding sites by Quirion et al. (1981) revealed preferential labelling of the 
cerebellar molecular layer. The discovery that [311]TCP preferentially bound to the 
cerebellar granule cell layer gave an early indication of potential differences in the binding 
properties of [3H]PCP and [3H]TCP in the cerebellum and led to the proposal that the two 
ligands had differing anatomical specificities (Vignon et al., 1986).  It is possible, 
therefore, that the high density of [3H]dextrorphan binding sites in the molecular layer 
correspond to autoradiographic localization of NMDA receptors at excitatory synapses on 
the dendrites of Purkinje cells in this brain region. Immunocytochemistry has recently 
revealed NMDAR1 specific labelling of Purkinje cell dendrites in the molecular layer of the 
cerebellar cortex (Brose et al., 1993). Furthermore, in situ hybridization studies have 
localized NMDAR1 mRNA in Purkinje cell bodies of adult rat cerebellum (Moriyoshi et al., 
1991; Laurie and Seeburg, 1994a). 
In summary, the anatomical distribution of [3H]dextrorphan recognition sites in rat 
forebrain corresponds to the known distribution of NMDA receptors labelled by NMDA-
sensitive [3H]glutamate, [3H]MK -801 and PlijTCP. We have, however, identified both 
regional and pharmacologic heterogeneity in the binding characteristics of [3H]dextrorphan 
which appears to reflect some degree of nonidentity between [3H]dextrorphan binding sites 
and those sites labelled by other noncompetitive antagonists. Given the increasing evidence 
for NMDA receptor heterogeneity, ligand autoradiography represents a powerful technique 
with the potential to resolve distinct populations of native NMDA receptors. 145 
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